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Chapter1:GeneralIntroduction


1.1WhatareBiomaterials?
“A biomaterial is a nonviable material used in a medical device intended to 
interact with biological systems” (D.F. Williams, 1987). 

This broad definition include nowadays different substances like metals, ceramics, 
polymers, and composites that are produced synthetically or biologically for use in the 
treatment or management of a disease, condition, or injury. Although biomaterials are 
primarily used for medical applications, they are also used to grow cells in culture, to assay 
for blood proteins in the clinical laboratory, in processing biomolecules in biotechnology, 
for fertility regulation implants in cattle, in diagnostic gene arrays, in the aquaculture of 
oysters and for investigational cell-silicon "biochips." The commonality of these 
applications is the interaction between biological systems and synthetic or modified natural 
materials. Moreover, biomaterials are rarely used on their own but are more commonly 
integrated into devices or implants. Considering this large range of applications is not 
surprising that the estimated worldwide market for biomaterials that was about $5 billion in 
1985,  grew to about $23 billion in 2005. [1,2] 
Biomaterials require generally several features, that can vary depending on the final 
application of the device. First, they need to be non-toxic, unless it is specifically 
engineered for such requirements (for example, drug delivery system that targets cancer 
cells to destroys them). They should be biocompatible, that is with a low level of immune 
response and with a good probability of clinical success of the whole device in which a 
specific biomaterial is part or its whole. They need the appropriate mechanical
requirements, like mechanical performance, mechanical durability and physical properties. 
Moreover, we must consider the pain of the patient related to possible inflammatory 
reactions due to the introduction of a foreign material or device in the body. Aiming to 
relieve discomfort and pain, a biomaterial should be compliant.
Finally, economical aspects have to be considered, since the research, clinical testing, 
regulatory clearance, manufacture, quality control, and distribution of medical devices 
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require large investment from the companies, which need to make a profit to fund all these 
activities.
The complex balance between the desire to alleviate suffering and death, the excitement of 
new scientific ideas, the corporate imperative to turn a profit, the risk/benefit relationship 
and the mandate of the regulatory agencies to protect the public impose the researchers a 
wide range of ethical considerations in developing new biomaterials. 




Figure 1.1. Examples of several biomaterial applications. [51] 






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1.2DrugDelivery

Drug delivery is the method or process of administering a pharmaceutical compound to 
achieve a therapeutic effect in humans or animals. [3] To obtain a determined behavior in 
drug administration, it is necessary to design systems with a specific drug release profile, 
absorption, distribution and elimination, taking into account safety and patient compliance. 
Most common methods of delivery include the preferred non-invasive peroral (through the 
mouth), topical (skin), transmucosal (nasal, buccal/sublingual, vaginal, ocular and rectal) 
and inhalation routes. Many pharmacological agents such as peptide and protein, antibody, 
vaccine and gene based drugs have to be delivered by injection, since using other routes 
they might be susceptible to enzymatic degradation or cannot be absorbed into the systemic 
circulation efficiently due to molecular size and charge issues. For instance, many bioactive 
molecules are rapidly degraded by enzymes in the stomach and in the intestine. 
Current efforts in the area of drug delivery include the development of targeted delivery in 
which the drug is only active in the target area of the body (for example, in cancerous 
tissues) and sustained release formulations in which the drug is released over a period of 
time in a controlled manner from a formulation.  
An important parameter in drug delivery is the release rate of the drug in the organism. The 
release of the active agent may be constant over a long period, it may be cyclic over a long 
period, or it may be triggered by the environment or other external events. In any case, the 
purpose behind controlling the drug delivery is to achieve more effective therapies while 
eliminating the potential for both under- and overdosing. Other advantages of using 
controlled-delivery systems can include the maintenance of drug levels within a desired 
range, the need for fewer administrations, optimal use of the drug in question, and 
increased patient compliance. While these advantages can be significant, the potential 
disadvantages cannot be ignored: the possible toxicity or non-biocompatibility of the 
materials used, undesirable by-products of degradation, any surgery required to implant or 
remove the system, the chance of patient discomfort from the delivery device, and the 
higher cost of controlled-release systems compared with traditional pharmaceutical 
formulations. The ideal drug delivery system should be inert, biocompatible, mechanically 
strong, comfortable for the patient, capable of achieving high drug loading, safe from 
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accidental release, simple to administer and remove, and easy to fabricate and sterilize. In 
general, a controlled-release systems must assure a high blood level of the drug over a long 
period of time. The main problem of the traditional drug forms is that frequent 
administration are required to keep the blood level of the agent between a maximum value, 
which may represent a toxic level, and a minimum value, below which the drug is no 
longer effective. In controlled drug delivery systems designed for long-term administration, 
the drug level in the blood remains constant, between the desired maximum and minimum, 
for an extended period of time. Depending on the formulation and the application, this time 
may be anywhere from 24 hours (Procardia XL®, for vasospastic angina) to 1 month 
(Lupron Depot®, for prostate cancer) to 5 years (Norplant®, contraceptive system). In recent 
years, controlled drug delivery formulations and the polymers used in these systems have 
become much more sophisticated, with the ability to do more than simply extend the 
effective release period for a particular drug. For example, current controlled-release 
systems can respond to changes in the biological environment and deliver (or cease to 
deliver) drugs with a determined rate, based on the external stimuli. Moreover, new 
materials are available nowadays that permit the targeting to specific tissues, or cells , or 
definite sites where the active agent is to be delivered.
1.3Biomaterialsfordrugdelivery

In the last 50 years, many biomaterials have been discovered, increasingly appropriated to 
be utilized in drug delivery systems. At the earliest stages of the research (years ’50 -’60) in 
biomaterials a few compounds displayed features suitable for medical applications. For 
example:
x Poly(ethylene) for toughness and lack of swelling.  
x Poly(methylmethacrylate) for physical strength and transparency.
x Poly(siloxanes) or silicones for insulating ability.  
x Poly(urethanes) for elasticity.
x Poly(vinyl alcohol) for hydrophilicity and strength.  
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x Poly(vinylpyrrolidone) for suspension capabilities. 
Afterwards, further materials have been discovered thank to the technological advances. 
The research focused on chemical inertia, lack of toxic impurities, minimal aging and ease 
of processing. Some of these are the following: 
x Poly(2-hydroxy ethyl methacrylate).
x Poly(N-vinylpyrrolidone).
x Poly(vinyl alcohol).  
x Poly(acrylic acid).
x Polyacrylamide.
x Poly(ethylene-co-vinyl acetate).
x Poly(ethylene glycol).  
x Poly(methacrylic acid). 
Nowadays, new classes of polymers that are able to degrade within the body are available. 
Moreover, a rational approach to the synthesis of new materials permits to tailor specific 
features  depending on the final application. Promising results were often obtained in 
clinical trials. Some of these biodegradable polymers are listed below.
x Polyanhydrides (Shieh et al., 1994)  
x Polyamidoamines (PAA) (P. Ferruti, A. M. Marchisio, R. Duncan, 2002) 
x Polyglycolides (PGA) (Okada et al., 1987).  
x Poly(lactide-co-glycolides) (PLGA).
x Polylactides (PLA) (Okada et al., 1987).
x Polyorthoesters (Heller et al., 2000) 
x Polyphosphoesters (Richards et al., 1991) 
x Polyphosphazenes (Allcock, 1994) 
A great advantage of biodegradable polymers is that they are broken down into biologically 
tolerable molecules that are metabolized and removed from the body via normal metabolic 
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pathways. However, biodegradable materials do produce degradation by-products that must 
be tolerated with little or no adverse reactions within the biological environment.
Chemical, physical and processing properties can affect the biodegradation of the polymer 
in the biologic environment. Some of these factors are the following: 
x Site of implantation.
x Morphology (amorphous/semicrystalline, microstructures, residual stresses).
x Storage history.  
x Sterilization process.  
x Annealing.
x Processing conditions.
x Physical factors (shape and size changes, variations of diffusion coefficients, 
mechanical stresses, stress- and solvent-induced cracking, etc.).
x Physicochemical factors (ion exchange, ionic strength, pH).
x Chemical structure.
x Chemical composition.
x Distribution of repeat units in multimers.
x Configuration structure.  
x Presents of ionic groups.  
x Presence of unexpected units or chain defects.  
x Molecular weight.
x Molecular-weight distribution.
x Adsorbed and absorbed compounds (water, lipids, ions, etc.).
x Presence of low-molecular-weight compounds.
x Mechanism of hydrolysis (enzymes versus water). 
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1.4ControlledReleaseSystems

A main aspect in drug delivery is represented by the release rate of the active molecule to 
the target. In most cases a stable blood level of the agent is required; in particular, this 
value must be between the toxic concentration and the minimum effective concentration. 
Controlled release systems permit not only a stable blood level, but also improve many 
aspects compared to the traditional drug forms. By comparison, the controlled release 
assure (1) a constant rate of drug release, offering a means to circumventing the problems 
of overdosing and underdosing inherent to conventional formulation. It requires (2) 
considerably less agent to produce a given duration or effect than does a conventional
system. A third important benefit is that (3) this technology makes possible both delivery of 
the agent locally and its containment at the site of action. In medicine, local delivery and 
containment reduce the dosage required and the possibility of side effects. A final 
advantage of controlled release is that (4) fewer application of the agent are required. It is 
widely recognized that a once-daily dosage regimen results in a significantly better patient 
compliance than multi-daily dosing, with a consequent improvement in the efficacy of the 
treatment.
There are three primary mechanisms by which active agents can be released from a 
delivery system: diffusion, degradation, and swelling followed by diffusion (figure 2). Any 
or all of these mechanisms may occur in a given release system.
Diffusion occurs when a drug or other active agent passes through the polymer that forms 
the controlled-release device. The rate controlling step can be the passage of the drug 
through the polymer matrix or through a selective film or a membrane. In the first case, the 
rate normally decreases with the time, whereas in the second case the drug delivery rate can 
remain fairly constant.
The degradable matrices are designed to degrade within the body as a result of natural 
biological processes. This capability eliminates the need to remove a drug delivery system 
after release of the active agent has been completed. The polymer degradation occurs 
usually by hydrolysis of covalent bonds of the macromolecular chain, producing smaller 
and biologically acceptable compounds. Degradation may take place through bulk 
hydrolysis, in which the polymer degrades in a fairly uniform manner throughout the 
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matrix. In other cases, as for example the polyanhydrides and polyorthoesters, the 
degradation occurs only at the surface of the polymer, resulting in a release rate that is 
proportional to the surface area of the drug delivery system.
Finally, swelling-controlled release systems are usually designed to be incapable of 
releasing its agent or agents they are placed in an appropriate biological environment. The 
swelling increases the aqueous solvent content within the formulation as well as the 
polymer mesh size, enabling the drug to diffuse through the swollen network into the 
external environment. One of the most useful feature of a polymer's swelling ability is that 
the swelling can be triggered by a change (pH, temperature, or ionic strength) in the 
environment surrounding and for most of these polymers the alteration can be reversible .  
Figure 1.2. Scheme of different drug release strategies: a) diffusion, b) degradation and c) 
swelling followed by diffusion. 
One of the greatest opportunities in controlled drug delivery lie in the sphere of 
responsive delivery systems, with which it will be possible to deliver drugs through 
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implantable devices in response to a measured blood level or to deliver a drug precisely 
to a targeted site. Much of the development of novel materials in controlled drug 
delivery is focusing on the preparation and use of these responsive polymers with 
specifically designed macroscopic and microscopic structural and chemical features. 

1.5CharacterizationofPolymers
As general rule, two parameters are fundamental to characterize a polymer: the number 
average molecular weight ( nM ) and the weight average molecular weight ( wM ). [24]
nM  is defined as the total weight of all molecules in a polymer sample divided by the total 
number of moles present. Thus the number-average molecular weight is: 
where Nj is the number of moles whose weight is Mj and nj is the mole fraction (or the 
number fraction) of molecules of size Mj.
wM  is defined as: 
where wj is the weight fraction of molecules whose weight is Mj.
The polydispersity (PD) of a polymer is defined as a ratio of weight average molecular 
weight divided by number average molecular weight. It is important to note that dealing 
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with a polymer sample we must always consider a distribution of molecular weights which 
is described by a ratio (PD). If all molecules of a polymer sample have the same molecular 
mass this ratio is 1 and the polymer is described as a monodisperse. This ratio is always  1 
and the higher this ratio, the broader is the distribution of molecular weights. Polymer 
conjugates must be rigorously characterized with respect to their molecular weight and PD 
because biodistribution and pharmacological activity are known to be molecular weight 
dependent. The most common method to investigate the average molecular weight of a 
polymer is the Size Exclusion Chromatography (SEC). 
Others fundamental characterizations in polymer chemistry are Nuclear Magnetic 
Resonance spectroscopy (NMR), MALDI-TOF spectroscopy, viscosimetry and High 
Performance Liquid Chromatography (HPLC). All the polymers must be fully 
characterized to be used in clinical evaluation. Moreover, the extensive characterization of 
the physico-chemical properties of a polymer, is a good starting point for the rationale 
design of a new compound related to that polymer. 
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1.6Bioconjugationofpolymers
In the past decade, conjugation of a polymer with a bioactive molecule has become a 
central issue in pharmaceutical sciences. For many years the starting point for developing a 
polymeric adduct was the Ringsdorf’s Model (Figure 1.3). [25] 
Figure 1.3. Ringsdorf’s model of polymer-drug conjugate. 
This model included a bioresponsive polymer-drug spacer that is stable during conjugate 
transport and able to release drug at an optimum rate on arrival at the target site, adequate 
drug carrying capacity in relation to the potency of the drug that must be carried and the 
ability to target the diseased cell or tissue by an active  or passive mechanism (see EPR 
effect, Chapter 1.8). In almost all recent structures developed, the “solubilizing group” has 
been replaced by the use of water soluble polymers. The targeting moiety is used to achieve 
an active targeting or it can be a tracking group, used for instance as fluorescent- or radio-
marker, to follow the behavior of the polymeric adduct in vitro and in vivo.
Chapter 1 
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The conjugation of a polymer with a drug or a bioactive molecule (bioconjugation) permits 
to obtain compounds with many useful features in drug delivery. Several examples of these 
benefits are the following: 
9 stabilization of labile active molecules from chemical and biological degradation. 
9 protection from proteolytic degradation. 
9 reduction of immunogeni city. 
9 decreased antibody recognition. 
9 increased plasma half life. 
9 modification of organ disposition. 
9 drug penetration into selected cell compartments through endocytosis. 
9 enhanced possibilities of drug targeting. 
The chemistry of bioconjugation is extensive because it deals with a large variety of 
molecules. Different approaches may be used depending on the properties of the bioactive 
molecule to be modified and of the ones of the ligand to be coupled. 
Despite the large variability that characterizes this field of chemistry, a common feature 
shared by the reactions used in bioconjugation is the fact that all of them must be carried 
out in mild conditions, so to avoid disruption of the properties of the conjugated active 
molecules. Generally, both the drug molecule and the polymer are not reactive by 
themselves and a preliminary step of activation is needed before coupling. In some cases, it 
may be necessary to introduce a new functional group in either drug or polymer molecule. 
This may be achieved either through a specific chemical reaction that transforms a 
functional group into the desired one, through the use of a difunctional reagent or, as in the 
case of proteins, through genetic recombinant techniques that allow the introduction of one 
amino acid with the desired reactivity (e.g.: the thiol function of cysteine or the amino 
group of lysine). There are many polymers used in the preparation of bioconjugates for 
pharmaceutical application. Because of their application in the biomedical field, they all 
share the common properties of being highly hydrated, non toxic, non immunogenic and of 
having a molecular weight sufficiently low to allow, when they are not biodegradable, 
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filtration through the kidney. If they have the property to be biodegradable, their 
degradation products must be non toxic and non immunogenic themselves. 
Although the polymers used in bioconjugation present different structures in their 
polymeric backbone, they have only a limited number of functional residues that are 
normally exploited in the coupling reaction. The most common anchoring groups are -
COOH, -OH and -NH2. These groups must be activated in order to react with the desired 
drug molecule and many mild activation methods are presently available. It might be 
necessary to activate the drug molecule instead of the polymer. The strategy adopted is 
determined by various factors including the best conditions for preserving drug activity and 
easiness of conducting the chemical steps of the reaction. Special attention must be paid to 
the 3-dimensional structure of the polymers, their hydrophobic/hydrophilic balance, their 
flexibility and biodegradability. All of these factors are important in dictating the fate of the 
drug in vivo, the rate of elimination from blood and the protection from degradation, both 
in vivo and in the pharmaceutical formulations. 
1.7PolymerTherapeutics

In recent years, polymer sciences have reached a high technological level in the synthesis 
of polymers, which can be specifically tailored depending on the target or the final 
application. The instrumental analysis techniques permit nowadays a reliable 
characterization of the polymers even at nanometric level. The biotechnology is making 
possible the production of a large quantity of pharmaceutically active proteins, that was 
unconceivable in the pre-genomic Era. All these factors contributed to the development of 
new classes of compounds, which cannot be contained in the definition of “drug delivery 
systems”. To describe these new systems a new term was coined: “Polymer Therapeutics”.
Polymer therapeutics (Figure 1.4)  have been authoritatively reviewed by Duncan et al. [4] 
These polymers can act as (1) polymeric drugs, [5] (2) polymer-drug conjugates, [6] (3) 
polymer-protein conjugates, [7,8] (4) polymeric micelles in which the drug is covalently 
bound to the polymer, [9] and (5) polymers used as non-viral vectors for intracellular 
delivery of genes and proteins. [10] 
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Figure 1.4. Scheme of several polymer therapeutics systems. 
To prepare polymer therapeutics different type of polymers can be used. A first division is 
between natural (e.g. polysaccharides and polyamino acids) [11,12] or synthetic (e.g. 
HPMA and PEG)[13,14,15]. Depending on the application, they might be inert or 
essentially biologically active[16]. The use of polymers as targetable drug carriers was first 
proposed by Ringsdorf. [17] The model is based on a hydrophylic polymer backbone, to 
which a targeting moiety is attached to promote cell-specific uptake. A polymer-drug linker 
that can be degraded at specific sites is also incorporated, liberating the drug in the required 
tissues at an appropriate rate.. The ideal polymeric carrier should possess the following 
qualities: (i) non-toxic, (ii) non-immunogenic, (iii) biodegradable, (iv) contain functional 
moieties which allow conjugation to therapeutic compound, (v) high drug loading capacity, 
(vi) resistant to premature degradation in bloodstream, (vii) simple to manufacture, (viii) 
able to control the molecular weight distribution, and (ix) stable as pharmaceutical 
formulation.
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Polymer–protein conjugates: 
Compound  Name Status Comment 
   
SMANCS Zinostatin 
Stimalmer
Market Hepatocellular carcinoma 
PEG–L-asparaginase Oncaspar Market Acute lymphoblastic leukemia 
PEG–GCSF Neulasta Market Prevention of neutropenia associated 
with cancer and AIDS chemotherapy 
PEG–interferon a 2a PEG-Introne Market 
Phase I/II 
Hepatitis B and C 
Melanoma, chronic myelogenous 
leukemia and renal cell carcinoma 
PEG–interferon a 2b PEG-Asys Market 
Phase I/II 
Hepatitis C 
Phase I/II Melanoma, multiple 
myeloma and renal cell 
Carcinoma 
PEG–arginine 
deiminase
ADI-PEG20 Phase I Hepatocellular carcinoma 
PEG–glutaminase
combined with a 
glutamine 
antimetabolite
6-diazo-5-oxo-L-
norleucine  
PEG-PGA
and DON 
Phase I/II  Various 
Polymer–drug conjugates: 
Compound  Name Status Comment 
   
Polyglutamate–
paclitaxel
CT-2103;
XYOTAX
Phase
II/III
Various, particularly non small cell 
lung cancer; ovarian cancer 
Polyglutamate–
camptothecin 
CT-2106 Phase I Various 
HPMA copolymer–
doxorubicin
PK1;
FCE28068
Phase II Various, particularly lung and breast 
cancer
HPMA copolymer–
doxorubicin-
galactosamine
PK2;
FCE28069
Phase I/II Particularly hepatocellular carcinoma 
HPMA copolymer–
carboplatin platinate 
AP5280 Phase I/II  Various 
HPMA copolymer–
DACH–platinate
AP5346  Phase I/II  Various 
PEG–camptothecin PROTHECAN Phase II  Various 

Table 1.1.   Examples of polymer–protein and  polymer–drug conjugates in clinical use in 
oncology. [18] 
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 The ideal polymer-drug conjugate (Table 1.1) must facilitate targeting in the body without 
initiating an adverse toxicological and immunological response. Biodegradable polymers 
enable repeated administration without concern over accumulation and potential cumulative 
toxicity. A polymer which has a high drug carrying capacity also helps to increase targeting 
efficiency. Moreover, for  pharmaceutical development an important requisite is the 
possibility of the up-scaling of the process. 
Anyway, several polymers do not have all these characteristics, but they may still be useful 
as targetable polymeric drug carriers. For example, although HPMA copolymers are non-
biodegradable, but limiting molecular weight to less than 40.000 ensures effective renal 
elimination. [19]
Compared to natural polymers, synthetic polymers have some advantages, particularly the 
versatility or design with variations in structure for cell-specific interaction. One of the 
most successful non-biodegradable polymers is PEG, [20] which is used nowadays in many 
pharmaceutical formulations. However, as a polymeric drug carrier, it has a low drug 
carrying capacity, therefore limiting its conjugation to potent drugs. Instead, in cancer 
therapy, biodegradable polymers are preferable because usually the accumulation in the 
target tissue is a fundamental strategy. The choice of polymers as macromolecular carriers 
therefore depends on the desired clinical application.


1.8PolymersforanticancertherapyandEPReffect
Polymer-drug conjugates have many advantages compared to conventional cytotoxic 
chemotherapy. Conventional chemotherapeutic molecules have low selectivity to tumour 
tissues due to their random distribution and passive diffusion through cellular membranes 
in the body. However, a major advantage of polymer-anticancer conjugates is their ability 
to target tumour tissues passively owing to the hyperpermeability and decreased tissue 
drainage of the tumour vasculature (EPR effect) (Fig. 1.4). The EPR phenomenon is 
dependent on both the characteristics of the conjugate, including the molecular weight [25, 
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26] overall charge [21, 22] and size, and the type of tumour vasculature involved[20]. 
Many polymer-anticancer compounds rely on the EPR effect for passive targeting to the 
tumour tissues [27, 28] (Figure 1.5) By targeting to the tumours, polymer-drug conjugates 
reduce drug toxicity in vivo and clinically. [29] In addition, polymer-drug conjugates may 
also overcome multidrug resistance (MDR) due to the different mechanism of cell uptake 
(endocytosis) as compared with small therapeutic molecule [30, 31, 32] therefore bypassing 
resistance at the membrane level. Many polymer-anticancer conjugates have shown 
effective antitumour activity in vivo, including the polyamino acids- [33, 34] PEG- [35] and 
HPMA [36, 37] copolymer-based systems.



Figure 1.5.  “Enhanced Permeability and Retention effect” (EPR). The macromolecules tend to 
concentrate in tumor tissue much more than in normal tissues, enabling the accumulation of the 
drug in the tumor. 

 In order to improve the passive targeting strategy employed by the EPR effect and to 
minimise toxicity against normal tissues, a targeting ligand attached to the  polymer should 
ghelp to promote better antitumour activity. These targeting motifs can be small peptides 
[38,39] and proteins. [39,40] As example, the galactosamine-containing HPMA copolymer-
doxorubicin (DOX) conjugate (known as PK2, see table 1.1) which targets the hepatocyte 
No drainage 
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asialoglycoprotein receptor (ASGPR) is currently in phase I/II clinical trial. [36] It is the 
only targeted polymer-drug conjugate in clinical development to date. This targeting 
strategy using a polymer-anticancer prodrug has been demonstrated by in vivo liver-
targeting in both animal [41] and human studies. [39]  
The success of delivering polymer-anticancer conjugates such as HPMA copolymer-DOX 
is based on the concept of lysosomotropic drug delivery. This relies on the endocytic 
uptake of the polymer-drug conjugate and transfer to the lysosome. Lysosomal cleavage of 
the GFLG peptidyl linker can release the DOX.  Then diffusion of DOX into the cytosol 
and nuclear interaction results in DOX-mediated cytotoxicity. Enzymatic degradation of 
peptidyl linker is not the sole mechanism of the drug release. Due to the low pH of the 
intracellular organelles, drugs can be released  from the polymer conjugates using a pH-
responsive polymer or an endsomolytic polymer such as PAAs that facilitate cytosolic 
access of the drug. 
1.9Endosomolyticpolymers
Exploiting the unique pH gradient of intracellular organelles, [42] endosomolytic polymers 
have been designed to be pH-responsive, and many have been used as non-viral gene 
delivery vectors. These polymers include the polycations e.g. poly(ethylenimine) (PEI), 
[43] poly(L-lysine) (PLL), chitosan, [44] poly(2-dimethylamino)ethylmethacrylate 
(PDMAEMA), [44] PAAs, [45] and poly(amidoamine) (PAMAM) dendrimers, [46] 
polyanions such as poly(propylacrylic acid) (PPAA) [47] and poly(ethylacrylic acid) 
(PEAA). [48] All rely on the ability to undergo pH-triggered conformational change to 
initiate membrane disruptive activity. 
In general, protonation of the cationic groups in pH-responsive cationic polymers results in 
polymer expansion and subsequent membrane destabilisation which allows the delivery of 
therapeutic agents to the cytosol. Such a mechanism is proposed for the membrane 
destabilisation behaviour of PAAs and other polycations. The “proton sponge” mechanism 
has been hypothesised to explain PEI membrane disruption. It is suggested that protonation 
of PEI causes an influx of anions (e.g. Cl- ions) into the endosome, followed by the influx 
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of water. Subsequent osmotic swelling destabilises the membrane, thereby permits the 
release of therapeutic agents to the cytosol . 
The cationic polymers, such as PEI and PLL are generally one to two orders of magnitude 
more toxic than PAAs. [49] They also have high haemolytic activity (>50%) at 
physiological pH (~ pH 7.4), which raises concern in respect of in vivo application. In 
contrast, the lower toxicity of PAAs, their pH-dependent membrane-lytic properties and 
ability to deliver genes and toxins [49] in vitro underline their potential as intracellular 
delivery. Therefore, the potential of using PAAs for targeted delivery of a toxin, gelonin, 
was assessed in this investigation. 
Internalisation by cells can be both a passive and energy-dependent process, which is 
crucial for the uptake of nutrients, removal of cell debris, homeostasis maintenance and cell 
signalling. The discovery of lysosomotropic delivery of macromolecules by de Duve in the 
1970s , and the presence of specialised enzymes in the lysosomal compartment, have 
provided a platform for the development of polymeric therapeutics that exploit the 
intracellular enzymes  and pH gradient (e.g. PAAs) for successful delivery of therapeutics. 
Therefore understanding the basic principles in the uptake of polymer conjugates into cells 
and their intracellular transport is essential in order to determine their mechanism of actions 
and to design better polymer therapeutics in the future. 
Since macromolecules are unable to diffuse across the plasma membrane, their cellular 
uptake is limited by the process of endocytosis. Endocytosis can be broadly defined as the 
entry of molecules into the cells. It can be generally divided into two groups: phagocytosis 
(cell eating; uptake of particles) and pinocytosis (cell drinking; uptake of fluid). 
Phagocytosis does not occur in all mammalian cell types. It is  employed by cells such as 
macrophages, neutrophils and monocytes for the uptake of large particles (>0.75 µm), 
including cell debris, apoptotic cells, foreign micro-organisms and parasites etc.  
On the other hand, pinocytosis (fluid-phase uptake) occurs virtually in all cells, and 
involves the constitutive uptake of the extracellular fluid and solutes by specific and non-
specific mechanism. Pinocytosis itself can also be subdivided into three main groups: fluid-
phase pinocytosis, non-specific adsorptive pinocytosis and receptor-mediated pinocytosis . 
While fluid-phase pinocytosis is characterised by the constitutive uptake of non-diffusible 
molecules in the extracellular environment, non-specific adsorptive pinocytosis is mediated 
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by non-specific binding of solutes to the cell membrane via ionic and 
hydrophilic/hydrophobic interactions with the cell membrane. Such mechanisms are though 
to mediate uptake of many polymer-drug conjugates. However, the efficiency of 
endocytosis can be further improved by receptor-mediated pinocytosis, which involves the 
capture of ligands via highly specific receptors located on the plasma membrane. Many 
proteins (e.g. low-density lipoprotein (LDL), transferrin), hormones (e.g. insulin, growth 
hormone), growth factors (e.g. epidermal GF), viruses (e.g. adenovirus and human 
immunodeficiency virus) and toxins (e.g. diphteria toxin) also exploit this route of entry 
into the cells. 
The complexity of these broadly classified uptake mechanisms is demonstrated by the fact 
that these processes are also subdivided into different endocytic pathways, including 
phagocytosis, pinocytosis, and receptor-mediated endocytosis, which are illustrated in 
Figure 1.6. 
Figure 1.6. Schematic illustration of different endocytic pathways.
General Introduction 

22

1.10EndocyticpathwayofpolymerǦdrugconjugates
The intracellular pathways are complex and dynamic, there is no absolute separation of the 
different intracellular compartments. The usage of terminology and some vesicle trafficking 
events studied in literature are still debatable. However, it is generally accepted that 
endocytosed molecules are processed through different intracellular compartments, 
principally sorting from early endosome (EE) to late endosome (LE) and subsequent fusion 
leading to the lysosomal compartment. Other intracellular organelles such as the Golgi 
apparatus, trans-Golgi network (TGN), cytoskeleton may also be involved. So, after the 
intracellular uptake of polymers into the cells, the polymers may undergo a series of 
intracellular sorting, vesicle fusion and degradation, depending on the pinocytosis pathway 
it undertakes and the nature of the polymer (e.g. endosomotropic or lysosomotropic). 
The progressively acidic environment of the intracellular compartments has wide 
implications for endosomotropic and lysosomotropic delivery systems, particularly when 
these systems are pH-sensitive or dependent on intracellular enzymes for activity. Upon 
endocytosis, molecules are first received by the EE, which are characterised by their 
tubulo-vesicular morphology, mildly acidic pH (ranging between pH 6-6.8) due to the 
presence of H+-ATPase pump [50] and specific membrane markers. Endocytosed materials 
are then sorted for recycling back to the cell surface via the tubules or transport to later 
compartments via the vesicular part of the EE. 
Captured materials are then brought to the late endosome as the final step in the sorting 
process before delivery to the lysosome. Late endosome contains the lipid 
lysobisphosphatidic acid and many membrane lamellae (membrane vesicles), which have a 
lower pH than early endosome, typically between pH 5-6. They also contain lysosomal 
proteins and degradative enzymes. 
The dense lysosomes (~0.5-2 µm) are considered to be the terminal station of the endocytic 
pathway and are the main site for degradative activity. They contain a high concentration of 
lysosomal enzymes, whose activities are optimal in the lysosomal membrane or are 
transported by specific carriers or channels.
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Chapter2:Poly(amidoamine)s
2.1Introduction
Biomedical polymers and polymer therapeutics rapresent a major impetus for innovation in 
many therapeutic areas such as cancer, inflammatory, and infective diseases. The search for 
new drug-delivery concepts and new applications are the major driving force in polymer 
therapeutics. Functional polymers have found many applications, for instance as ion-
exchange resins and agents for surface modification of heparin filters and non 
thrombogenic surfaces. [1-3] These systems are just entering early clinical evaluation. [4-6]
The poly(amido-amine)s (PAAs) are one unique family of synthetic functional polymers 
that have been widely developed for use both as biomedical  materials and polymer 
therapeutics. PAAs are synthetic ter-amino polymers obtained by stepwise polyaddition of 
primary or secondary aliphatic amines to bis-acrylamides  (Scheme 2.1). 
Scheme 2.1 synthesis of PAAs. 
The PAAs synthesis is performed in solvents carrying mobile protons, such as water or 
alcohols, at temperatures over about 10-15° C and without added catalysts. [7-9] High 
monomer concentrations and relatively low reaction temperatures give the best results. 
Aprotic solvents, even if highly polar, are unsuitable as reaction media as they yield only 
low molecular weight products. The amino groups react only if present as free base. The 
synthetic mechanism is a Michael type addition (Scheme 2.2). 
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Scheme 2.2.  Michael type addition mechanism 
Both primary mono-amines and secondary bis-amines lead to linear polymers. Under non-
selective conditions bis-primary amines usually give crosslinked products on reaction with 
bis-acrylamides, that is, they react as tetrafunctional monomers. However, it has been 
reported that under special conditions including low reactant concentrations, low initial 
temperatures, and an excess, on a molar basis, of bis-amines, soluble PAAs carrying 
secondary instead of tertiary amino groups in their main chain can be obtained. These 
PAAs have been found to provide suitable soluble carriers for drug attachment. [10] The 
structures of some  PAAs are reported in Table 2.1.  
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Table 2.1.Some examples of PAAs. [8] 
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2.2FunctionalisationofPAAs
PAAs are inherently highly functional polymers. However, further functionalization of 
PAAs may be useful for special purposes. In many cases, the introduction of additional 
functions in PAAs as side substituents can be simply achieved starting from the 
corresponding functionalized monomers. The presence of hydroxy-, tert-amino-, allyl-, 
amido- and ether groups, in the monomers do not interfere with the polymerisation process. 
The structures of some functionalised PAAs are reported in Table 2.2. 
Table 2.2.Functionalised PAAs. [9]
However, to obtain PAAs functionalized with chemical groups as side sostituents such as 
SH, NH2 NHR and PH2, an indirect pathway is required. In particular, starting from the 
results of a kinetic study on the addition reaction of N,N-dimethylacrylamide to the side D-
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amino groups of partially protonated poly-L-lysine, [11] it has been shown in a previuos 
work that PAAs carrying primary amino groups as side substituents (exemple 7, Table 2.2), 
can be prepared by using as monomer 1,2-bis-aminoethane in its mono-protonated form. 
[12] Owing to the sharp difference among the two basicity constants of 1,2-bis-
aminoethane, little or no di-protonated molecules are present in solution and only one 
amino group per molecule is initially available for the addition reaction. This reaction 
lowers the pKa of the amino group involved, making it improbable that the same group will 
subsequently assume a proton by exchange reaction with a protonated one. Only the amino 
group already substituted remains in its unprotonated form and can react further, and the 
behaviour of mono-protonated 1,2-bis-aminoethane in PAA synthesis approaches that of a 
primary monoamine. We have found, in fact, that by adjusting the reaction conditions 
essentially linear polymer with primary amino groups as side substituents can be obtained 
from 1,2-diaminoethane and probably also from other bis-primary amines, if a sufficient 
difference exists between their ionisation constants.
2.3AmphotericPAAs
Amphoteric PAAs are polyamidoamines carrying acidic functions as side substituents, in 
most cases carboxyl groups.  
They are obtained by using either carboxylated bis-acrylamides or aminoacids as 
monomers. In both cases, a stoichiometric amount of strong base must be added to the 
monomer mixture. As regards aminoacids, natural D-aminoacids other than glycine yield 
only oligomeric products, but the polyaddition reaction proceeds reasonably well with all 
aminoacids bearing no substituents on the carbon atom in D-position, as well as with 
peptides in which the first aminoacid residue fulfils the same condition.
Amphoteric PAAs present a unique interest as bioactive polymers. Besides being generally 
less toxic than purely cationic PAAs of similar structure, in solution they change their net 
average charge as a function of pH. By a proper choice of the starting monomers, the acid 
and basic strength of the amino and the carboxyl groups can be controlled in such a way 
that the polymer passes from a prevailingly anionic to a prevailingly cationic state during a 
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relatively modest pH change. For instance this would occur when amphoteric PAAs are 
internalised by cells via the endocytic pathway. During this time they are transferred from 
extracellular fluids of pH 7.4 to intracellular compartments where the pH is lowered to  6.5 
(endosomes) and  then ~ 5.0 (lysosomes). Moreover, PAAs that become prevailingly 
cationic at lower pH can also be designed to become membrane-active and thus they 
display endosomolytic properties. 
The structures of some amphoteric PAAs deriving from aminoacids are reported in Table 
2.3 and amphoteric PAAs deriving from 2,2-(bis-acrylamido)acetic acid are reported in 
Table 2.4. 
Table 2.3.Amphoteric PAAs deriving from amino acids. [7, 51] 
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Table 2.4. Amphoteric PAAs deriving from 2,2-bis(acrylamido) acetic acid. [13] 
PAAs in which the amido and ter-amino groups are not regularly distributed along the 
macromolecular chain have been synthesised by poly(acylation-addition) of piperazine and 
other bis-secondary amines, with various activated derivatives of acrylic acid. [14,15] 
"Alternating" PAAs, in which one amino-group is strictly followed by one amido-group all 
along the macromolecular chain have also been synthesised. [15]  
Polymers structurally related with PAAs were obtained by substituting either bis-acrylic 
esters, [16] or divinylsulphone [17] for bis-acrylamides or hydrazine [18] or phosphines 
[19] for amines.Other polymers, of poly(amino-ketone) structure, were obtained by 
polycondensation of ketonic bis-Mannich bases with bis-amines, [20-22] as reported in 
Table 2.5.  
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Table 2.5. tert-Amino polymers structurally related with PAAs. [20-22] 
The ring-opening addition reaction of bis-secondary amines, or primary mono-amines, to 
ethylene sulphide gave a new family of monomers, namely 2,2'-
alkylidenediiminodiethanethiols. [23] These monomers, besides polymerising by 
polyoxidative coupling, [23] could be employed in polyaddition reactions with bis-
acrylamides, bis-acrylic esters, or divinylsulphone, in a way formally similar to that used 
with bis-secondary amines. [24-26] 
The polyaddition proceeded also with bis-methacrylic esters [27] and bis-
methacrylamides[28], that are extremely sluggish in reacting with bis-amines under the 
usual conditions of PAA synthesis. The structures of some selected sulfur-containing 
polymers structurally related to PAAs are reported in Table 2.6.  
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Table 2.6. Sulfur-containing tert-amino polymers structurally related with PAAs. [24-26] 
By considering the synthetic process leading to PAAs it’s evident that if the hydrolytic  
cleavage  of the main backbone during polymerisation is minimised the end-groups of the 
products are either sec-amino-, or acrylamido groups. Therefore, by performing the 
polymerisation reaction with an excess of one of the two monomers, PAAs prevailingly or 
totally terminated with either of the two groups (A-PAAs and V-PAAs, respectively) can 
be obtained. End-functionalised PAAs can be employed for preparing block and graft 
copolymers, as well as crosslinked resins, and therefore can be regarded as 
macromonomers. A careful end group analysis performed by NMR on samples of a model 
PAA obtained with different monomer ratios [29] showed that the well known relation 
between the limit number-average polymerisation degree X n  and the initial stoichiometric 
ratio r of the monomers [30]: 

ܺ௡തതതത ൌ 
ଵା௥
ଵି௥     Equation 2.1 
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was true only with excess amine. The average molecular weight (see section 1.5) of the 
products obtained with initial excess bis-acrylamide was invariably higher than expected. 
This might be explained by the occurrence, during polymerisation, of some hydrolytic 
cleavage of the amido groups, preferentially involving the terminal acrylamido groups 
while sparing internal amido groups. This process would partly substitute amino groups for 
acrylamido ones, thus reducing the excess of the latter and re-adjusting to some extent the 
stoichiometric balance. The acrylic acid eventually produced should not compete with the 
acrylamido groups for the addition of the amino groups. The double bond of acrylic acid, in 
fact, is comparatively unreactive towards amines under basic conditions. 
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2.4ChemicalpropertiesofPAAs
The number-average and weight-average molecular weight (see section 1.5) of the PAAs 
described thus far were in the range 5,000÷30,000 and 10,000÷50,000 respectively, with a 
dispersity index (depending from the isolation method) usually in the range 1.5 - 2. [34, 35] 
For example, when the polymerization products of series of differently disubstituted 
diamines with the same bisacrylamide, 1,4-bis-acryloyl-piperazine or the sodium salt of 
2,2-bis-acrylamido-acetic acid, were compared it was shown that their molecular weight 
diminished with increasing steric hindrance on the nitrogen atoms. The effect of 
nucleophilicity of the nitrogen atoms apparently plays a minor role in determining overall 
molecular weight reached. [7] This is not surprising. The polymerisation reaction is the 
Michael addition, that is, an equilibrium reaction mostly affected by the reactant 
concentration and steric hindrance.  
As mentioned above, when water is used as the polymerisation solvent for the polyaddition 
reaction, it proceeds fastest and gives the highest molecular weight products. For reactions 
carried out in aqueous media, the molecular weight increases with the reaction time until it 
reaches a maximum, after which it steadily decreases. This is not surprising, as in water the 
polyaddition reaction competes with the hydrolytic cleavage of the amidic bonds. The 
maximum attainable molecular weight in water depends on both monomers concentration 
and reaction temperature, being higher for higher concentrations and lower temperatures. 
At higher temperatures the maximum is attained quicker, but is lower. [7] 
PAAs are usually soluble in water as well as chloroform, lower alcohols, dimethylsulfoxide 
and other polar solvents. However, amphoteric PAAs dissolve only in water. The intrinsic 
viscosities of PAAs in organic solvents or aqueous media usually range from about 0.15 to 
1 dl/g. As a rule, PAAs exhibit relatively large hydrodynamic volumes in solution if 
compared with polyvinyl polymers of similar molecular weight, indicating a tendency to 
assume an extended chain conformation in solution.
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2.5PAAsaspolyelectrolytes
PAAs can be regarded as polyelectrolytes since they posses ter-amino groups in the main 
chain. Normally, the values of the protonation constants (logK) of polyelectrolytes depend 
on the degree of protonation of the whole macromolecule; that is, they follow the modified 
Henderson-Hasselbach equation: 
ܭ௜ ൌ ܭ௜ι ൅ ሺ݊ െ ͳሻ  ቂ
ሺଵିఈሻ
ఈ
ቃ          Equation 2.1 
where logKi° is the protonation constant of a group present in a completely unionised 
polymer. The protonation constants of polyelectrolytes are usually referred to as “apparent” 
constants, as opposed to the “real” constants of non-macromolecular acids and bases. [33] 
However, in most PAAs the results of the potentiometric titrations are consistent with n
values very close to 1. This means that in PAAs the tendency of the aminic nitrogens of 
each repeating unit to assume a proton in practice does not depend on the degree of 
protonation of the whole macromolecule. Therefore these groups behave as if belonging to 
a small molecule. [37-49] Consequently, “real” basicity constants can be determined. The 
number of the basicity constants of PAAs is equal to the number of the aminic nitrogens 
present in their repeating unit, and their values are similar to those found for the non-
macromolecular models of PAAs, prepared by hydrogen-transfer addition to 4-
acryloylmorpholine of the same amines used in the preparation of the corresponding PAA. 
The basicity constants of some representative PAAs are reported in Table 2.7. 
Structure Polymer pKa1 Polymer pKa2 Model pKa1 Model pKa2
Entry 5 of Table 2.1 8.09 4.54 8.25 4.80 
Entry 3 of Table 2.2 8.80 4.11 9.05 4.35 
Entry 3 of Table 2.1 7.01 2.98 7.12 2.39 
Entry 1 of Table 2.1 7.79 - 8.07 - 
Entry 4 of Table 2.1 9.02 7.91a) 9.05 8.34b)
a) pKa3 = 4.46, pKa4 = 2.12 
b) pKa3 = 4.42, pKa4 = 2.43 
Table 2.7. Basicity constants of some PAAs and their non-macromolecular models at 25°C in 0.1 
M NaCl solution. [8] 
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The unusual behaviour of PAAs in the polyelectrolytes domain is probably due to the 
relatively long distance between the amino groups belonging to different units combined 
with the high charge-sheltering efficiency of the two amido groups interposed. It is 
noteworthy that a single amido group bound to a piperazine ring, as in the polymer shown 
in the scheme 2.3, is not sufficient to minimise interactions between neighbouring units. In 
fact it exhibits a typical polyelectrolyte behaviour. [50] 
Scheme 2.3.  Poly(1,4-piperazinediyl-1-oxo-trimethylene) 
Differently from “normal” PAAs, amphoteric PAAs deriving from aminoacids and 
therefore carrying both carboxyl- and amino-groups attached to the same monomer tend to 
exhibit a typical polyelectrolyte behaviour. [51] This tendency is less pronounced for 
amphoteric PAAs in which the carboxyl groups and the amino groups are attached to 
different monomers. [13]
2.6Heavymetalionscomplexingbehaviour
Many PAAs are able to form coordination complexes with heavy metal ions, such as Cu2+,
Ni2+, Co2+. "Real" stability constants could be determined for PAAs also in the case of 
complex formation. [37, 38, 43, 44, 48, 49, 52]
Only those PAAs (with the exception of PAAs derived from aminoacids) containing at least 
two aminic nitrogens per repeating unit that neither belong to a cyclic monomer nor are 
separated by more than three methylene groups are capable of  complex-formation. The 
electronic and e.p.r. spectra of both polymeric and non-polymeric complexes obtained from 
PAA models were similar, and consistent with an octahedral tetragonally distorted 
structure, in agreement with the substantial independence of the repeating units of the 
C N NCH2CH2
O
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polymers in the complex formation process. Crosslinked PAA resins retain ion-complexing 
ability similar to those of the corresponding linear polymers. [53-55] 
2.7DegradationbehaviourofPAAsinaqueousmedia
All PAAs, containing amidic bonds in their main chain are degradable in aqueous solution. 
The degradation of several PAAs (structures shown in Tables 2.1 and 2.4) has been studied 
by means of viscometric and chromatographic techniques. [56, 57] The structure of both 
the aminic and amidic moieties has an influence on the degradation rate. For instance, in 
PAAs containing 2-methylpiperazine moieties, the rate of decrease in viscosity observed 
was in the order 4 (Table 2.1) > 10 ( Table 2.2) > 1 (Table 2.4) (Figure 2.2). 
Figure 2.2. Degradation behavior of some representative PAAs at 37°C in 0.2 M phosphate buffer, 
investigated by viscometric measurements. [83] Initial weight-average molecular weights were 
approximately: 28000 (PAA-1, squares), 19000 (PAA-2, circles), 16500 (PAA-3, triangles), as 
measured by means of SEC with PAA-1 calibration.[29] 
ߟ௦௣Ȁܥ
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As the aminic portion of each PAA was the same, it can be concluded that the PAA derived 
from BAC was the most stable. This trend was confirmed by further studies on several 
other PAAs having different aminic monomers coupled with the same three amidic 
monomers. [57, 58] We have observed in many instances that additional ter-aminogroups 
or carboxylate groups, if present as side substituents, increase the degradation rate of 
PAAs. However, we do not have at present any clear evidence that the degradation rate of 
PAAs is affected by the basicity of the amino groups present in the macromolecular 
backbone.
The mechanism of PAA degradation seems to be purely hydrolytic as no vinyl groups, such 
as those which would have derived from a E-elimination reaction, could be determined by 
NMR analysis. [29] Moreover, the degradation rate was not affected by the presence of a 
20-fold excess 2-mercaptoethanol (on a molar basis). This would have affected degradation 
if mercaptoethanol was able to act as scavenger of any activated double bonds resulting 
from a E-elimination-mediated degradation. In addition, it has been demonstrated that 
degradation of PAAs in aqueous media is strongly influenced by pH but does not seem to 
be affected by the presence of isolated lysosomal enzymes at pH 5.5. [84]  
Bioreducible PAAs have been also recently developed [83, 85] that are able to undergo 
reductive degradation in presence of a reductive agent such as mercaptoethanol, 1,2-
dithiotreitol and glutathione. These PAAs were obtained by using disulfide linkages 
containing monomers as cystine, cystamine or N,N’-bisacryloylcystamine. Therefore, these 
polymers are able to be degraded, giving low molecular weight species, in the intracellular 
environment. 
2.8BiomedicalapplicationsofPAAs
 PAAs were first developed in the biomedical field in relation with their ability to form 
stable complexes with heparin. More recently water soluble PAAs used as polymeric drugs, 
polymer drug carriers (particluarly anticancer conjugates and as pH-responsive polymers 
which display endosomolytic characteristics and therefore have potential for use as non-
viral vectors for intracytoplasmic delivery of proteins and genes. 
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2.8.1PAAsaspolymertherapeutics
Water soluble PAAs have been examined as anticancer agents in their own right [59] 
polymer-drug conjugates (particularly as anticancer conjugates) and as endosomolytic 
vectors for intracellular delivery of genes and toxins. [60, 83, 84] Before water soluble 
polymers can be seriously studied for parenteral administration it is essential to establish 
their biocompatibility in respect of route and frequency of administration and the end 
application. 
Although many polycations such as poly-L-lysine, polyethyleneimine and amine 
terminating PAMAM dendrimers have been explored as drug and oligonucleotide delivery 
systems, [61-63] they are generally very toxic to cells in culture. For example poly-L-lysine 
displays IC50 values in the range 1-60 Pg/ml depending on the cell type, and incubation 
time [64] and poly L-lysine, polyethyleneimine and PAMAM dendrimers showed 
signficant haemolytic activity which is molecular weight- (generation-) dependant. [63-64]  
Early studies examined the cytotoxicity of PAAs derived from piperazine or N,N'-bis (2-
hydroxyethyl)ethylenediamine. Although these polymers were less cytotoxic than poly-L-
lysine, [100] the more recently described amphoteric PAAs shown in Table 2.4 are even 
less toxic (Table 2.8). ISA23, BAC -DMEDA and BAC -DEEDA were >100 times less 
cytotoxic than the non-amphoteric aminic polymers used as a reference. [13, 66] 
Polymer ܯ௪തതതത IC50  (mg/ml ± SD) 
Dextran 72000 >5 
ISA 23 42710 >5 
BAC-DMEDA 28960 >5 
BAC-DEEDA 30310 >5 
BAC-DMEPDA 11420 3.55 ± 0.31 
BAC-DMEXA 30860 0.23 ± 0.06 
Poly(L-lysine) 56500 0.05 ± 0.061 
Poly(ethyleneimine) 70000 0.01 ± 0.01 
Table 2.8. Cytotoxicity of amphoteric PAAs against B16F10 melanoma cells. [13] 
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At pH 7.4 ISA23 has ~ 50% of its units in L- and ~50% in LH± form, so the polymer 
would have a relatively large negative average charge. Similarly at pH 7.4 BAC-DMEDA 
and BAC-DEEDA would be prevailingly negatively charged with more than 90% of units 
in the L± form13. This charge effect would explain their lack of toxicity; supported by the 
observation that BAC-DMEPDA and BAC-DMEXA, which are positively charged at pH 
7.4, are more cytotoxic than the other PAAs. Comparing the IC50 values of BAC-DMEDA 
and BAC-DEEDA it would appear that a modest increase in hydrophobicity does not 
significantly induce toxicity. Cytoxicity is most closely related to the net positive charge 
present at physiological pH i.e. the fraction of repeating units present in LH2±+ form. As 
the log˚K2 (relating to the protonation of the second amino group) increases and 
approaches physiological pH, so does polymer-mediated toxicity (Table 2.8). This general 
conclusion is supported by the observation that hydrogen-transfer polyaddition of N,N-
dimethylacrylamide to the side amino groups of poly L-lysine also resulted in a sharp 
decrease of toxicity. [11] 
As PAAs are degradable in the main chain [31, 32] and are relatively non-toxic this would 
suggest potential for parenteral administration and use as polymer-based therapeutics. 
However, before further studies were warranted it was necessary to demonstrate that PAAs 
could display an appropriate pharmacokinetic profile, i.e. a plasma residence time and 
tissue- or disease-specific targeting appropriate to proposed application. To study 
biodistribution analogues of the PAAs ISA 1 and ISA 23 [66] were synthesised to contain 
approximately 1 mol% 2-p-hydroxyphenylethylamine. These polymers were named ISA 4 
and ISA 22, respectively. [66] After intravenous (i.v.) injection to rats 125I-labelled ISA 4 
was immediately taken up by the liver (> 80% recovered dose at 1h) whereas 125I-labelled
ISA 22 was not (liver uptake was <10% recovered dose at 5h) (Table 2.9). The longer 
circulation time of ISA 22 relative to other cationic polymers provides opportunity for use 
in tissue targeting either by the incorporation of receptor-targeting ligands e.g. galactose 
moiety [67] or by passive means such as the enhanced permeability and retention effect 
(EPR) . [68-70] 
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Body district 
Percent localization 
ISA 22a) ISA 4b)
After 1 h After 5 h After 1 h After 5 h 
Blood ൎ 70 % ൎ 20 % ൎ 1.5 % ൎ 0 % 
Kidney ൎ 2 % ൎ 1 % ൎ 7 % ൎ 4 % 
Liver ൎ 10 % ൎ 8 % ൎ 83 % ൎ 85% 
Lungs ൎ 2 % ൎ 4 % ൎ 4 % ൎ 3 % 
urine ൎ 13 % ൎ 65 % ൎ 0 % ൎ 5 % 
a) The structure of ISA 22 is the same as that of Isa 23 (see Table 2.4), in which 3 mol-% of 2-methylpiperazine units 
have been replaced by tyramine units to allow iodination. 
b) The structure of ISA 4 is the same as that of Isa 1 (entry 4 of Table 2.1) in which 3 mol-% of 2-methylpiperazine 
units have been replaced by tyramine units to allow iodination. 
Table 2.9. Body distribution of 125I-labelled PAAs after intravenous injection in rats. [66] 
Tumour targeting by the EPR effect occurs due to the fact that circulating macromolecules 
(proteins or synthetic polymers) are unable to cross the walls of normal capillary vessels 
but are able to extravasate into tumour tissue due to their leaky angiogenic vasculature. 
This phenomenon has already been shown to cause significant tumour targeting of N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer conjugates containing doxorubicin 
[69] and platinates [71].  Biodistribution studies in mice bearing subcutaneous B16F10 
melanoma showed that 125I-labelled ISA 22 was still accumulating in tumour tissue after 5h 
(2.5% dose/g). The so-called "stealth" properties of ISA 23 are probably due to its 
zwitterionic nature with prevailingly negative charge at pH 7.4.
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2.8.2PAAsǦanticancerconjugates
Early in the 1970’s several PAAs  (structures shown in Table 2.10) were shown to display 
inherent antitumour activity. [59]
Table 2.10.Structures of PAAs tested for antimetastatic activity. [59]
After i.v. administration PAAs 1-4 of Table 2.10 were toxic. Nevertheless, they could be 
administered to mice at a dose of 20 mg/Kg, and showed activity in reducing the number 
and average weight of Lewis lung (but not Sarcoma 180) tumor metastases. However, PAA 
5 was not toxic, and moreover at a dose of 200mg/Kg was able to reduce the number and 
average weight of both Sarcoma 180 and Lewis lung tumor metastases. Although activity 
was observed in the metastatic models no activity was observed against the primary 
tumour. 
Following the rationale adopted for design of other polymer-drug conjugates [72] more   
recently   PAAs have systematically been developed as water soluble carriers for known 
anticancer agents including mitomycin C (MMC) [73] and platinates. [74]   
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2.8.3NonǦviralvectorsforintracytoplasmicdelivery
Intracytoplasmic delivery of macromolecular drugs, particularly proteins and genes remain 
a challenge that must be overcome if we are to capitalise on advances in the understanding 
of the molecular basis of diseases. [75] Although viral vectors mediate effective 
transfection they have disadvantages including random insertion into host genome, 
potential immunogenicity [76] and low gene carrying capacity,  many non-viral delivery 
systems including cationic lipids and polymers are relatively toxic and also rapidly localise 
to lung or liver after i.v. administration thus abrogating their ability to target other tissues. 
Additionally, in most of the cases they display very poor transfection efficiency. This has in 
part been attributed to their inability to efficiently permeabilise the endosomal membrane. 
[77] Efficient cellular targeting and also localisation to the appropriate subcellular 
compartment is vital if these new approaches are to be converted into useful medicines. 
Addition of fusogenic peptides to the culture medium can increase transfection efficiency 
[78, 79] and it has been suggested that polymeric transfection agents such as 
polyethyleneimine can also facilitate transfection by swelling within the endosome causing 
membrane rupture, the so-called “proton sponge effect. [79]  
Unlike many other polyamines (e.g. polyethyleneimine and poly L-lysine), protonation and 
de-protonation of the repeating units along the PAA backbone are independent events thus 
providing the ability to tailor molecules with very sharp basicity constants. This peculiarity 
means that PAAs bearing two aminic nitrogens in their repeating unit show a marked 
conformational change during movement from a neutral to acidic pH. This effect is most 
pronounced when the aminic nitrogens are separated by only two methylene groups. [47]  
To investigate whether PAAs are able to permeabilise the endosomal membrane and thus 
aid cytoplasmic entry, the ability of PAAs to mediate DNA or  toxin delivery was studied. 
[80, 81, 83] Surprisingly, due to their amphoteric nature at pH 7.4, the PAAs ISA 1 and 
ISA 23 formed torroid shaped interpolyelectrolyte complexes (IPECs) of diameter 80 -150 
nm in diameter  (10:1 polymer excess) which were visible using TEM [80] (Figure 2.3).  
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Figure 2.3: TEM images of PAA/DNA complexes. (a) Lipofect ACE (scale bar 67 nm), (b) poly(l-
lysine) (scale bar 67 nm), (c) ISA 22 (scale bar 45.5 nm), (d) ISA 4 (copolymeric PAA obtained by 
polyaddition of a mixture of N,N9-bis(2-hydroxyethyl) ethylenediamine and 2-methylpiperazine 
(50 : 50) to 1,4- diacryloylpiperazine; scale bar 140 nm), and (e) plasmid (scale bar 67 nm). [80] 
The complexes displayed retarded electrophoretic mobility and also the ability to protect 
DNA from DNAse II degradation. At a polymer:DNA ratio of 10:1 the extent of inhibition 
of degradation was in the range 92.2 ± 11.2% (ISA 4) - 58.0 ± 10.0% (ISA 23) (Figure 
2.11).
In transfection experiments, the PAAs demonstrated the ability to mediate pSV E-
galactosidase transfection of HepG2 and COS-7cells.  An ISA23 complex of ISA23: DNA 
mass ratio of 5:1 showed equivalent transfection ability compared with polyethyleneimine 
and LipofectIN, and was more effective than LipofectACE. [80] Moreover, recently 
developed cationic PAAs containing  disulfide linkages in the main chain showed a 
significantly higher transfection efficiency compared with polyethyleneimine.[83] 
Recent studies are focusing on precise definition of the intracellular trafficking of PAAs 
with a view to quantitation of their intracellular fate. It is also necessary to find definitive 
proof that PAAs do break the endosomal membrane. These studies are difficult as it is hard 
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to find a good marker of the endosomal membrane. Lysosomes are more easily identified 
due to the presence of lysosomal enzymes in their interior. Isolation of rat liver lysosomes 
following administration of ISA23 and ISA4 have shown that internalisation of PAA into 
the lysosomal compartment destabilises the lysosomal membrane resulting in increased 
fragility and enzyme escape. [82] Interestingly incubation of PAAs on the outside of 
isolated lysosomes does not have this effect suggesting that differential membrane 
structure, inside versus outside, must play a role in membrane destabilisation. However, the 
precise mechanism of PAA membrane perturbation warrants more detailed mechanistic 
study  if PAA structure is to be optimised further.
2.9Conclusions
In conclusion we can say that PAAs are an extremely versatile family of step-addition 
polymers. Their facile synthesis and functionalisation allows production of many diverse 
linear, crosslinked and blocky or grafted polymers. Thus, PAA chemistry can easily be 
tailored to suit specific applications. PAAs are being developed for many biomedical 
applications.
Many PAAs have features rendering them particularly suitable for use as soluble polymer-
drug conjugates. Their hydrophilicity allows solubilisation of hydrophobic drugs and 
functionality allows attachment of pendent drug moieties, targeting groups or diagnostic 
moieties. The high hydrodynamic volume of PAAs and their ability to prepare 'stealth" 
polymers provide the opportunity for significant tumour targeting by the EPR effect. As 
PAAs are bio degradable this allows parenteral injection of high molecular weight 
polymers without risk of long-term accumulation in the body and moreover the amphoteric 
polymers display minimum general cytotoxicity or haemolytic activity at pH 7.4. The 
toxicity of the ultimate degradation products of PAAs was not investigated; however, they 
are unlikely to be produced in significant amounts within the body since the polymers will 
be eliminated first upon reduction of their molecular weight. 
PAAs are particularly suitable for a use as intracytoplasmic/endosomolytic delivery 
vectors. They have "real" basicity constants which can be tailored depending on the aminic 
monomers selected, resulting in a predictable charge situation as a function of pH. This is 
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particularly important in a sharp change when passing from pH 7.4 (blood) to pH 5.5 or 
less within the intracellular endosomal and lysosomal compartments. At pH 7.4, 
amphoteric PAAs behave as zwitterions with a zero- or a slightly negative net average 
charge. They undergo conformational change as a function of degree of protonation leading 
to "opening" of PAA coil after cellular internalisation. This unique characteristic can be 
used to release of a drug payload and assist delivery of macromolecular drugs into the 
cytosol.
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Chapter3:PolymerǦcoatedferromagneticnanoparticlesfor
cancertherapy
3.1Abstract
A group of novel amphoteric PAAs was synthesized by Michael addition reaction of three 
amines, 2-methylpiperazine (MP), N,N’-ethylenediamine-diacetic acid (EDDA), 2-
aminoethyl-phosphonic acid (AP) with two different bisacrylamides, N,N’-
bisacrylamidoacetic acid (BAC) and N,N’-bisacryloylpiperazine (BP). These polymers were 
obtained with different values of average molecular weight (ܯഥ௡: 5000, 15000, 30000, 
50000) by varying the stoichiometric ratio of the starting monomers. Each polymer was then 
evaluated as coating agent of Magnetite and Cobalt-Ferrite nanoparticles. The coating tests 
showed that only the BAC containing polymers stabilized the colloidal suspension in water 
and in physiological solution. The BAC-EDDA - coated Magnetite nanoparticles showed 
the highest stability also after 24 h, yielding particles with an  average size around 30 nm 
(by Dynamic Light Scattering) and good values of hyperthermic efficiency (by a S600 
SQUID magnetometer). These results encourage further studies on PAA-nanoparticles 
systems to investigate the biological properties (i.e. biocompatibility) and magnetic 
performances (hyperthermia) by in vitro and in vivo tests. 
3.2Introduction
Over the past few decades, nanoparticles, which exhibit significantly distinct physical, 
chemical and biological properties from their bulk counterparts, have elicited much interest.  
For cancer diagnosis and therapy there are currently a number of techniques based on 
different types of nanoparticles [1-6]. Nanotechnological advances in cancer research, 
diagnostics and therapy, improved direct visualization of malignant cells, targeting at 
molecular level and safely delivering large amounts of chemotherapeutic agents to the 
desired cells. These techniques should be capable of rapid and sensitive detection of 
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malignant cells at early stages. The common feature of all nanoparticle-based cancer 
therapies is the need of specific NPs for achieving the desired therapeutic effect. However, 
each diagnostic/therapeutic technique requires a different chemical or physical property of 
the particles involved, which depends on the specific function played by the NPs in that 
therapy (e.g., vector, porous receptacle, heating agent, magnetic moment carrier, etc.). 
Sometimes the particle function is activated using an external agent (magnetic field, light, 
radiation, etc.) that interacts with the NPs.
Magnetic nanoparticles (MNPs) are one sub-class of this broad cancer-therapy designed 
NPs. Since the MNPs have a size comparable to the DNA or subcellular structures, this field 
opened the door for cell separation strategies using magnets as external driving force. 
Similarly, recent advancements on binding chemistry of biological units onto MNPs surface 
and the engineering of particle’s surface/shape have opened new exciting possibilities for 
drug delivery with high selective vectors. At present, most applications of MNPs are based 
on the following physical principles:
• The utilization of the magnetic moment of the MNPs as a disturbance of the proton 
nuclear resonance (e.g., contrast media for Magnetic Resonance Imaging, MRI).. 
• The positioning of MNPs in targeted organs or tissues (e.g. tumor) by application of 
controlled magnetic field gradients. 
• The magnetic losses of nanometric particles in colloids for heating purposes 
(Magnetic Fluid Hyperthermia, MFH). 
MRI is very useful in diagnosis and in following the course of therapies. It can produce 
images of both hard and soft organs. MRI contrast agents are often used and there are a 
number of potential compounds for infusion or injection. Basically there are three ways in 
which a contrast reagent may act. (i)It may not enter or attach to cells and simply act as an 
indicator of fluid-filled space e.g. the knee capsule. (ii) It may attach to the outside of cells 
(cell membrane) or (iii) may be taken into the cells. Closely related to these biological 
differences are the routes by which the agent reaches the target area. The high magnetic 
moment and the versatility of MNPs make them an attractive platform as contrast agents for 
MRI[16].
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The localizability of the particles by applying external magnetic fields is noteworthy in 
many types of therapy, for instance drug delivery or hyperthermia. The MNPs can be  
actively directed to a specific tissue after intravenous (i.v.) injection. The final localisation 
of the particles could be intracellular in many cases. Though the fate of nanoparticles in the 
intracytoplasmic environment is not completely clear, it was demonstrated by in vitro and in 
vivo experiments that cells can survive the presence of such particles in moderate loadings 
for moderate periods of time [17]. 
Moreover, MNPs can be heated up by a time varying magnetic field, making them useful 
for Thermotherapy, and in particular for Magnetic Fluid Hyperthermia. 
Magnetic Fluid Hyperthermia (MFH) is a technique in which MNPs are used to induce 
apoptosis and death in cancer cells exploiting their enhanced heat sensitivity compared to 
healthy cells, due to the poor development of blood vessels within the cancerous tissues[18]. 
The heat released by the particles upon application of an alternate magnetic field (usually in 
the frequency range 50–500kHz) is sufficient to increase the temperature in the tumor mass 
to values between 42 - 46°C for a few minutes, inducing cell apoptosis [19]. To this 
purpose, the best performing nanoparticles are those containing  metal oxides. Among these 
oxides, it was found that Magnetite (Fe3O4) and Cobalt-Ferrite (CoFe2O4) can provide 
nanoparticles with a higher hyperthermic efficiency.  Anyway, in vivo applications of MNPs 
involve subtle problems related to the response of a living organism to alien objects as, for 
instance, the immunological reaction, aggregation in arteries (embolism) and release of 
toxic metal ions as Nickel or Cobalt. 
Polymers Coated Nanoparticles can overcome all these drawbacks. In fact, using 
amphoteric PAAs (see Section 2.3) it would be possible to obtain nanoparticles with the 
fundamental features they require to be used in cancer therapy. The properties contribution 
of PAAs coating to magnetic NPs are the following: 
• making NPs colloidal suspension stable.  
• making NPs biocompatible. 
• making NPs stealth at antibodies. 
• enabling NPs to drug delivery.  
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Amphoteric PAAs can be synthesised containing one or two relatively weak tertiary amino 
groups and one or more strong carboxyl group per repeating unit. These PAAs are 
predominantly anionic in extracellular fluids, owing to the incomplete ionisation of the 
amino groups and complete ionisation of the carboxyl groups at pH 7.4. [7] When injected 
in experimental animals, they avoid rapid clearance by the reticuloendothelial system; that 
is, these PAAs are endowed with ‘‘stealth’’ properties, and concentrate by passive targeting 
at the level of tumors. [8] However, after internalization in cells, the same PAAs undergo 
conformational changes caused by variation of the pH value, which was around 7.4 in 
extracellular fluids, and around 5.5 within the cells. [9] It has been also demonstrated that 
PAAs can act as promoters of the intracellular trafficking of toxins such as Ricin A chain 
and gelonin.[10] It may be added that, unlike many lipidic vectors [8,11,12] and 
polycationic polymers,[13] PAAs can be purposely prepared to be nontoxic in vitro [8,14] 
and in vivo. [15] Furthermore, PAAs do not show the immunogenicity disadvantage of 
naked nanoparticles. Therefore, amphoteric PAAs can be of fundamental importance in the 
development of new nanoparticle-based systems for cancer diagnosis and therapy. 
In this Chapter the synthesis and the characterization of a series of novel amphoteric PAAs 
and the method for coating magnetic nanoparticles with these polymers are presented. This 
study was done in collaboration with Colorobbia Italia S.p.A., (Italy).
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3.3ResultsandDiscussion
A great number of methods is available  to produce nanoparticles of magnetite or cobalt 
ferrite: sol–gel method [21], microemulsion with oil in water micelles [22] or reverse 
micelles [23], aqueous precipitation and calcinations [24], combustion [25], and forced 
hydrolysis in a polyol medium [26]. 
In this widespread scenario, we started a project aimed to design new biocompatible 
nanomaterials based on PAA-coated ferromagnetic nanoparticles to be used in the magnetic 
hyperthermic treatment of tumor cells and eventually as contrast agents for MRI. The first 
step of this project involves the characterisation of the structural and physical properties of 
the magnetic core before the assembling of coating polymers. Colorobbia optimised the 
synthesis of ferromagnetic nanoparticles, based on the polyol technique with the seed 
method proposed by Sun [27], to obtain nanoparticles with controlled size in the range 5-
200 nm and high hyperthermic efficiency. [20, 36, 37] 
In particular, Magnetite (MAG-NP) and Cobalt-Ferrite (CoFe-NP) nanoparticles were 
selected for coating tests with PAAs. These nanoparticles were synthesised by Colorobbia 
and furnished in diethyleneglycol (DEG) solution at 3 wt% of magnetic material.
3.3.1PAAssynthesisandcharacterisation
To provide stability in solution and biocompatibility to the ferromagnetic nanoparticles 
presented above, different kinds of amphoteric PAAs were studied as coating agents. In 
particular, 5 homopolymers were synthesised by Michael addition reaction of three amines,
2-methylpiperazine (MP), N,N’-ethylenediamine-diacetic acid (EDDA), 2-aminoethyl-
phosphonic acid (AP) with two different bisacrylamides, N,N’-bisacrylamidoacetic acid 
(BAC) and N,N’-bisacryloylpiperazine (BP) (Figure 3.1). Moreover, the effect of the 
molecular weight of the polymer on coating ability was also investigated. To this purpose, 
each polymer was obtained with the number average molecular weight (ܯഥ௡) of about  5000, 
15000, 30000 and 50000 (only for ISA23).  
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Figure 3.1. Synthetic scheme of PAAs. Abbreviations: BAC, 2,2-bisacrilamidoacetic acid; BP,
N,N’-bisacryloylpiperazine; MP, 2-methylpiperazine; EDDA N,N’-ethylenediamine-diacetic acid; 
AP, 2-aminoethyl-phosphonic acid. (a), H2O, LiOH, pH 9.5, N2, 3 days, r.t.; (b), H2O, NaOH, pH 
9.0, N2, 7 days, r.t.; (c), H2O, NaOH, pH 8.5, N2, 5 days, r.t.
The polymerisations were carried out in water, with a mild base and under inert atmosphere 
for several days. During the polymerisation the viscosity gradually increased and in all cases 
gelation was not observed. In order to consume any unreacted acrylamide groups after 
polymerisation 20 mol% excess morpholine was added into the reaction mixture, lasting the 
reaction overnight. The polymers were isolated by exhaustive ultrafiltration, followed by 
freeze-drying. The resulting PAAs have an excellent solubility in water. All the polymers 
obtained were characterised by NMR spectroscopy and Gel permeation chromatography 
(GPC) measurements . The 1H NMR spectra showed that the compositions of these 
polymers are in full accordance with the expected structures (Figure 3.1). No signals 
between 5 and 7 ppm, corresponding to the acryl group, were observed, indicating that the 
PAAs are all end-capped with amino groups. The average molecular weights ranged from 
about 5,000 to 50,000 (calculated by GPC with Pullulan standard). 
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These monomers were chosen since they displayed a good ion complexation ability 
(unpublished data). Moreover, is known from previous work that only those PAAs (with the 
exception of aminoacids derived PAAs) having aminic nitrogens that neither belong to a 
cyclic monomer nor are separated by more than three methylene groups are capable of  
complex-formation. The electronic and EPR (Electron Paramagnetic Resonance)  spectra of 
both polymeric and non-polymeric complexes obtained from PAA models were similar, and 
consistent with an octahedral tetragonally distorted structure, in accordance with the 
substantial independence of the repeating units of the polymers in the complex formation 
process. [28-30] 
3.3.2ControlofthePAAsaveragemolecularweight
In order to obtain polymers with controlled molecular weight and low polydispersity, three 
methods were tested: (1) fractionation by solvent/non-solvent chemical separation, (2) 
fractionation by ultrafiltration, and (3) controlled molecular weight syntheses. 
The method (1) was tested on BAC-EDDA and ISA23 to obtain fractions of polymer with 
controlled molecular weights and weight distributions. To avoid aggregation of the 
polymeric chains, the polymer was dissolved in a MeOH-H2O 9:1 saturated solution of 
LiCl. As it was known that the low solubility of the polymeric chains in acetone was 
dependant on the molecular weight (i.e. macromolecules with higher molecular weight were 
less soluble then those of lower molecular weights) the addition of slowly increasing 
amounts of acetone to a polymer solution gave the fractionation of the polymer sample. 
Afterwards, the polymer fractions were ultrafiltered by a 1000 cutoff membrane and freeze-
dried to eliminate the organic solvents and the LiCl. The GPC traces of the different 
fractions of ISA23 and BAC-EDDA are shown in Figure 3.2 (a) and (b), respectively.
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Figure 3.2 (a). GPC chromatograms of three different fractions of ISA 23 obtained by solvent non 
solvent fractionation. (a), ܯ௡തതതത: 10300; (b), ܯ௡തതതത: 7800; (c), ܯ௡തതതത: 5100. The peaks around 19 minutes 
are due to air dissolved in the sample’s solution. 
Figure 3.2 (b). GPC chromatograms of two different fractions of BAC-EDDA obtained by 
solvent/non-solvent fractionation. (a), ܯ௡തതതത: 6200; (b), ܯ௡തതതത: 5600. 
The solvent/non-solvent chemical separation yielded a good fractionation of the ISA 23 
sample. Nevertheless, with the same method it was not possible to obtain a good 
reproducibility and fraction separation of BAC-EDDA (Table 3.2). This is probably due to 
the different solubility in the utilised solvents of the two polymers. 
In the method (2), the polymer was ultrafiltered using membranes with a decreasing cutoff 
value (Amicon ultrafiltration system, Millipore).  In particular, the polymer was ultrafiltered 
firstly with 100,000 cutoff membrane, subsequently the obtained eluate was ultrafiltered 
again with a 30,000 cutoff membrane and so on, repeating the procedure with 10,000 and 
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5,000 cutoff membranes. The obtained fractions were freeze-dried and analysed by GPC. As 
example, the GPC traces of the different fractions of BAC-EDDA are shown in Figure 3.3. 
Figure 3.3. GPC chromatograms of four different fractions of BAC-EDDA obtained by 
ultrafiltration. (a), ܯ௡തതതത: 41000; (b), ܯ௡തതതത: 22600; (c), ܯ௡തതതത: 12300; (d), ܯ௡തതതത: 6500. 
A good separation of the fractions of BAC-EDDA was obtained by ultrafiltration. The yield 
of the fractions compared to the starting polymer were: a) 3%, b) 65%, c) 22%, d) 9%. The 
average molecular weight of the fractions was lower compared to the nominal cutoff of the 
related membrane (Table 3.1). This is due to the lower hydrodynamic volume of the 
proteins used for the membranes’ calibration.
In the method (3) the molecular weight was controlled by varying the stoichiometric ratio of 
the starting monomers in the polymerisation reaction. The average molecular weight of the 
polymers was controlled by adjusting the stoichiometric ratio “r” of the starting monomers 
(amines, bisacrylamides) to obtain different degrees of polymerisation “ തܺ௡” (Equation 1). 
[31] 
r
rX n 
 
1
1
                  Equation 1
Where:
       
x
o
B
o
A
N
Nr  
x N°A: number of function of monomer in defect  
x N°B: number of function of monomer in excess 
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Each polymer solution was then acidified at pH 4, ultrafiltered with a 5,000 cutoff 
membrane and freeze-dried. As example, the GPC traces of different batches of BAC-
EDDA are shown in Figure 3.4. The polymers thus produced had a number average 
molecular weight (ܯഥ௡) of about  5000, 15000, 30000 and 50000 (only for ISA23) 
respectively, and good values of polydispersity (PD) were obtained (from 1.5 to 2.0).
Figure 3.4. GPC chromatograms of four different batches (a, b, c, d) of BAC-EDDA obtained by 
controlled molecular weight polymerisation. (a), ܯ௡തതതത: 45200; (b), ܯ௡തതതത: 20000; (c), ܯ௡തതതത: 14000; (d), 
ܯ௡തതതത: 6700. 
In table 3.1 the GPC data related to the different fractionation methods are summarised. The 
method (1) yielded a good fractionation with ISA 23, nevertheless these results were not 
reproducible with other tested PAAs. A good separation and low PD values were obtained 
using the methods (2) and (3) with all the polymers synthesised. However, the method (3) 
resulted the best in order to obtain a specific average molecular weight since this technique 
allowed a more precise control of the final MW of the polymer. Moreover, this procedure 
was quicker and gave higher yields compared to method (2). 
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Method Sample Fraction ࡹ࢔തതതത ࡹ࢝തതതതത PD
1 ISA 23 a 10300 13800 1,34 
  b 7800 10900 1,40 
  c 5100 8500 1,67 
1  BAC-EDDA a 6200 8400 1,35 
  b 5600 7500 1,34 
2 BAC-EDDA a 41000 68000 1,66 
  b 22600 29800 1,32 
  c 12300 15600 1,27 
  d 6500 7400 1,14 
3 BAC-EDDA a 45200 77100 1,71 
  b 20000 33200 1,66 
  c 14000 19700 1,41 
  d 6700 9900 1,48 
Table 3.1. GPC data of the fractions obtained with the tested methods. method 1, fractionation by 
solvent/non-solvent chemical separation; method 2, fractionation by ultrafiltration; method 3
controlled molecular weight syntheses. The GPC traces of the fractions are showed in the figures 
3.5, 3.6 and 3.7. 
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3.3.3FunctionalisationofPAAs
In order to obtain PAAs able to undergo further functionalisations, we modified the 
syntheses by adding a small amount of amines carrying functional groups. In particular, ISA 
23 and BAC-EDDA were obtained as copolymer with the 5 - 10 mol%  of tyramine, 
ethylenediamine  or  ȕ-CD respectively. The general synthetic scheme is shown in Figure 
3.5. 
Figure 3.5. General synthetic scheme of the studied copolymers.
Tyramine has a primary amino group, thus it can be used as monomer without further 
functionalisations or protecting groups.The introduction of tyramine in the PAAs allows the 
radiolabelling of the polymer, which is a technique of fundamental importance in cancer 
therapy, e.g. to investigate the polymer distribution after i.v. injection in vivo [32].
Ethylenediamine posses two primary amino groups, therefore, to obtain linear polymers it 
was necessary to protect one of them with a protecting group which  must be stable under 
the conditions of PAA synthesis, that is, under alkaline conditions, but easily removable 
under conditions not affecting PAA stability. We selected  triphenymethyl group as a 
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protecting group. Thus, the starting monomer was 1-triphenylmethylamino-2-aminoethane 
(TPHMAE), prepared as previously described [33]. By this procedure, the PAAs become 
suitable as polymer carriers for carboxylated drugs as well as amenable to the labeling 
techniques by fluorescent probes commonly employed for proteins. 
ȕ-Cyclodextrin (ȕ-CD) has no amino groups itself. Therefore a preliminary functionalisation 
to obtain the mono-6-deoxy-6-amino-ȕ-cyclodextrin (ȕ-CD-NH2)  was necessary. The 
synthetic pathway leading to ȕ-CD-NH2 and the related 1HNMR spectrum are shown in 
Figure 3.6 and 3.7, respectively.  
ȕ-CD has found a number of applications in drug release. In fact, ȕ-CD is able to form host-
guest complexes with hydrophobic molecules because of the unique nature imparted by 
their structure. Thus, a PAA with ȕ-CD as side substituent would be able to complex water 
insoluble drugs and permit the solubilisation in water, enabling an easier delivery to the 
target tissue [34].  
Figure 3.6. Synthesis of ȕ-CD-NH2
For copolymerisations including tyramine, usual conditions adopted in PAA preparation 
were used. To the reaction mixture 5 mol% of tyramine was added, together with the 
required amount of the secondary diamine (MP or EDDA) in order to maintain the 
stoichiometric ratio between the amine functions and the double bonds of the bisacrylamide. 
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The copolymerisation  reaction including TPHMAE required a different solvent because of 
its poor solubility in water due to the presence of the triphenylmethyl group. Thus, 
TPHMAE and the bisacrylamide in a 1/20 ratio were dissolved in methanol. After a 1 day 
reaction, water-soluble oligomers were obtained. Water was then added to methanol (see the 
Experimental Part) up to a water/MeOH ratio of 2/1and the secondary diamine (MP or 
EDDA) was added allowing the polymerisation to proceed in the usual way for PAAs. In all 
cases, after polymerisation (3 days), the triphenylmethyl protecting group was cleaved by 
treating with aqueous hydrochloric acid. Pure ISA23-NH2 and BAC-EDDA-NH2 were 
finally obtained as hydrochlorides removing the by-product triphenylmethylcarbinol 
through solvent extraction, ultrafiltration, and freeze-drying. It can be noticed that the 
related copolymers (Table 3.2) obtained from the same bisacrylamides and secondary 
diamines  have a considerably higher molecular weight compared to ISA23-NH2 and BAC-
EDDA-NH2. This indicates a relatively low reactivity of TPHMAE towards the 
polyadditions reaction. In fact, the TPHMAE/bisacrylamide ratio of 1/20 was used to force 
the addition reaction. It was considered that after 1 day reaction most of the TPHMAE was 
transformed into an ABA trimer, in which A and B stay as bisacrylamide with a terminal 
double bond and a TPHMAE units, respectively.
The copolymerisation of ȕ-CD was carried out under normal condition used for the 
synthesis of the related homopolymers. We encountered some reproducibility problems due 
to hygroscopicity of ȕ-CD, since a stoichiometric ratio between amines and bisacrylamides 
is necessary to obtain polymers with high molecular weight. ȕ-CD-NH2 was then dried 
under N2 flow at 40°C for 24 h and the purity was checked by titration of the amino groups 
with HCl 0.1 M (see appendix) just before the addition to the reaction mixture. Copolymers 
of ISA 23 and BAC-EDDA were synthesised with 5 or 10 mol% of ȕ-CD-NH2 (compared 
to the total amount of amine). The structures and the average molecular weights of the 
synthesised polymers are shown in Table 3.2. The polymers were characterised by NMR 
spectroscopy (1H, 13C) and GPC analysis. 
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Name Structure ࡹ࢔തതതത ࡹ࢝തതതതത PD
ISA23-tyr 11300 14700 1,30
BAC-EDDA-tyr 15300 19000 1,24
ISA23-NH2 3500 4900 1,40
BAC-EDDA-
NH2 3200 4100 1,28
ISA23- ȕ-CD-5 25100 47300 1,88
ISA23- ȕ-CD-3 24100 39600 1,64
BAC-EDDA-
ȕ-CD 
21800 29700 1,36
Table 3.2. Structures and average molecular weights of the obtained copolymers. 
As example, the 1HNMR spectra (Figure 3.8)  and the GPC traces (Figure 3.9) of 
copolymers ISA 23-ȕ-CD-5 and ISA 23-ȕ-CD-3 (obtained from BAC, MP and 5 or 10 
mol%  of ȕ-CD-NH2, respectively), are shown.
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Figure 3.7. HNMR spectra of ȕ-CD-NH2.
Figure 3.8. HNMR spectra in D2O of a) ISA 23-ȕ-CD-5 and b) ISA 23-ȕ-CD-3
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Figure 3.9. GPC traces of a) ISA 23-ȕ-CD-5, b) ISA 23-ȕ-CD-3 and c) ȕ-CD-NH2.
The GPC chromatograms show that there is no free ȕ-CD in the polymer samples. 
Moreover, from the NMR spectra it was possible to calculate an amount of 2.5 mol% of ȕ-
CD in the ISA 23-ȕ-CD-3 and of 5.0 mol% in the ISA 23-5-ȕ-CD. Thus, only the 50 % of 
the starting monomer (5 mol% and 10 mol%, respectively) reacted with the bisacrylamide. 
In the case of BAC-EDDA-ȕ-CD the final amount of ȕ-CD in the polymer was 8 mol%, 
starting from 10 mol%. This is probably due to the different reactivity of the ȕ-CD-NH2
monomer compared with 2-methylpiperazine or EDDA, respectively. The related 1HNMR
spectrum is shown in Figure 3.10. 
Chapter 3 
69
Figure 3.10. HNMR spectrum in D2O of BAC-EDDA-ȕ-CD.
3.3.4NanoparticlesCoatingtests
The coating tests were performed in collaboration with Colorobbia. The particle size (by 
Dynamic Light Scattering, DLS) and hyperthermic efficiency measurements were carried 
out by Colorobbia. 
 The magnetic nanoparticles selected for coating tests were Magnetite (Mag-NP) and 
Cobalt-Ferrite (CoFe-NP) nanoparticles. The NPs were obtained from the synthesis [20] as 
stable colloidal solution in diethyleneglycol (DEG). Preliminary tests showed that the NPs 
were not able to produce stable suspension in water, therefore complexation tests were run 
as follows:  nanoparticles in diethyleneglycol (DEG) (0.2 g in 40 ml of solvent) were added 
dropwise to an aqueous solution of the polymer (1.2 g in 200 ml) under stirring. 
Ultrafiltration tests with Amicon (Millipore) were not appropriate since caused fast 
aggregation and then precipitation of the NPs. This is due to the magnetic field necessary to 
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the rotation of the stirring bar. Good results were obtained instead with dialysis tubes 
(30.000 cutoff) that allowed the elimination of low molecular weight species and the 
organic solvent (final concentration of DEG in water,  0.1%).. 
All the polymers shown in Figure 3.1 were used in coating tests and for each polymer, 
batches with different average molecular weights were also tried (Table 3.3).
Polymer ࡹ࢔
തതതത ࡹ࢝തതതതത PD Stabilisation of the NPs solution 
ISA 23 
4500
16800
33900
49000
7900
21300
55000
97000
1.76
1.27
1.62
1.98
Stable solution 
BAC-EDDA
6700
11000 
20000
9900
15500
33200
1.48
1.41
1.66
Stable solution 
BAC-AP 
3700
12400
22500
5000
17900
33500
1.35
1.44
1.49
Stable solution 
BP-EDDA
5800
14300
25200
9300
22500
41900
1.60
1.57
1.66
Non stable solution 
BP-AP 
5100
17300
20600
7200
23000
25800
1.41
1.33
1.25
Non stable solution 
Table 3.3. PAAs used in nanoparticles coating tests. 
Stable colloidal solutions of coated nanoparticles were obtained with BAC containing 
polymers (ISA23, BAC-EDDA, BAC-AP). In particular, BAC-EDDA showed the higher 
stability. Instead, BP containing polymers caused aggregation of the particles and then 
precipitation.
It was also found that generally the polymers with a value of ܯ௡തതതത around 15000 yielded the 
narrowest particle size distribution. However, all the polymers tested were not able to 
minimise the Cobalt release in Cobalt-Ferrite nanoparticles under non toxic values. 
Therefore, further investigations were carried out only on coated magnetite nanoparticles 
(average size: 10 nm by DLS). The particle size measurements (by DLS) of Magnetite NPs 
with BAC-EDDA and BAC-AP in water and in physiological solution are shown in Figure 
3.11 a-d. 
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Figure 3.11 (a). DLS measurement of Mag-BAC-AP (ܯ௡തതതത: 12400) in water 
.
Figure 3.11 (b). DLS measurement of Mag-BAC-AP (ܯ௡തതതത: 12400) in physiological solution. 
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Figure 3.11 (c). DLS measurement of Mag-BAC-EDDA (ܯ௡തതതത: 11000) in water. 
Figure 3.11 (d). DLS measurement of Mag-BAC-EDDA (ܯ௡തതതത: 11000) in physiological solution. 
BAC-EDDA showed a slightly narrower particle size distribution both in water and in 
physiological solution compared to BAC-AP, whereas the effect of the solvent on the size 
distribution was negligible. 
The Magnetite nanoparticles coated with BAC-EDDA (Mag-NP-BAC-EDDA) were used 
for hyperthermic efficiency measurement. This test was performed also on Mag-NP-BAC-
EDDA in presence of cis-diammineplatinum (II) dichloride (Cisplatin), an anticancer agent 
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(Table 3.4).  The Cisplatin/nanoparticles weight ratio in the coating reaction mixture was 
1/2. 
Sample Solvent
Hyperthermic 
efficiency of Non-
coated NPs (°C)
Hyperthermic 
efficiency of Coated
NPs (°C)
Mag-NP-BAC-EDDA
Physiological
solution 
5.05 4.51 
Mag-NP-BAC-EDDA + 
Cisplatin
Physiological
solution 
5.05 3.89 
Table 3.4. Hyperthermic efficiency of BAC-EDDA coated Mag-NP with and without Cisplatin.
Hyperthermic efficiency measurements have been carried out with irradiation at 170 KHz and with 
a magnetic field of 21 KA/m2 for 30 seconds. 
The conjugates showed an average size compatible with other kind of nanoparticles used in 
clinical trials for cancer therapy. The hyperthermic efficiency was decreased by the polymer 
coating (10%), but is still comparable with the values relevant to other systems commonly 
studied for magnetic hyperthermia. [35] At the moment in vitro tests are in progress. In 
particular, the stability of the coated nanoparticles in DMEM medium, and subsequently, 
the hyperthermic efficiency on different cell lines will be investigated.
3.4Conclusions
A series of new amphoteric PAAs was synthesised and characterised. Different methods to 
vary the average molecular weight of the polymers and to obtain a low polydispersity were 
investigated. By using the method of the molecular weight control by varying the 
stoichiometric ratio of the starting monomers it is possible to finely tune the MW of the 
polymer and obtain high yields and good PD values.  
These PAAs were used as coating agents in nanoparticles coating tests. The BAC containing 
polymers (ISA23, BAC-EDDA and BAC-AP) yielded stable colloidal solutions. Among the 
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others, BAC-EDDA, and in particular the one with a ܯ௡തതതത of 11000, conferred the highest 
stability to nanoparticles. 
Magnetite nanoparticles coated using BAC-EDDA yielded very stable solutions and good 
values of hyperthermic efficiency. The decrease of the NP’s hyperthermic efficiency due to 
the coating polymer was 10 %, thus the final value is still comparable with other systems 
studied in Magnetic Hyperthermia. 
We obtained PAAs also as copolymers with 5-10 mol% of ȕ-Cyclodextrin, tyramine and 
ethylenediamine. These copolymers, used as coating agents, enable the nanoparticles to 
drug delivery, radiolabelling and further functionalisations. Moreover, the carboxylic acid 
and amine functional groups of the polymer can facilitate attachment of binding partners 
(e.g., antibodies) to the polymer, which can allow the polymer-coated nanoparticle to be 
used in a variety of applications including protein detection and cell labeling. Further 
developments of functionalised magnetite NPs are under investigation for hyperthermic 
applications in locoregional cancer therapy and as carriers of pharmaceutical compounds for 
magnetic drug targeting. Part of this work has been published in an international patent [36].
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Chapter4:Poly(amidoamine)scontainingpeptidesinsertedin
themainchain.
4.1Abstract
A general method for preparing linear high polymers bearing in their main chain peptides is 
reported in this section. Peptides can be transformed into DZ-difunctional monomers in 
Michael-type stepwise polyadditions with bis-acrylamides by adding one or two cysteine as 
terminal residues. This provides a general method for preparing linear high polymers of 
peptides where the peptide moieties, connected by short hydrophilic bis-acrylamide-derived 
linkers, constitute the main portion of the polymer chain. To demonstrate the feasibility of 
this synthetic procedure the following model compounds for cysteine-modified peptides 
were used: reduced and oxidised glutathione, RGDC, CRGDC, ISLHAC and CISLHAC 
peptide sequences.  Novel series of polymers structurally related to PAAs in which the 
peptide represents the main constituent, were obtained. Moreover, the kinetic aspects of 
these reactions were considered. 
In preliminary biological tests these polymers showed a negative zeta potential at 
physiological pH, negligible values of cytotoxicity and haemolytic activity.  Further In 
vitro tests to investigate the biological properties of these polymers in comparison with the 
parent peptides are in progress. 
4.2Introduction
Malignant cellular transformation is largely viewed as the consequence of autonomous cell 
genetic alterations, leading to the activation of oncogenes and the inactivation of tumor 
suppression genes and increasing genomic instability, which gives rise to a cell capable of 
limitless proliferation and survival, invasion, and metastasis. [1] In addition, the process of 
formation of a tumor-associated vasculature (angiogenesis) has been recognised as an 
essential event promoting tumor progression. In the absence of tumor angiogenesis, tumors 
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enter a state of dormancy, characterised by a balance between cell proliferation and 
apoptosis. [2] During the last decade, significant advances have been made in the 
understanding of the tissue, cellular, and molecular events that regulate and mediate tumor 
angiogenesis. Many extracellular, cell surface, and intracellular molecules modulating 
angiogenesis have been identified and characterised, including growth factors and growth 
factor receptors, and especially vascular integrin inhibition showed very promising 
characteristics in antiangiogenic therapy.
Integrins are heterodimer transmembrane receptors for the extracellular matrix composed of 
an alpha and beta subunit. Antagonists of integrin Įvȕ3 have been shown to inhibit tumor 
angiogenesis and disrupt metastasis [4]. In addition, Įvȕ3 integrin antagonist can be 
radiolabeled and selectively localised in the tumors for diagnostic imaging.  These 
encouraging preclinical results stimulated researchers and industry to develop 
pharmacologic inhibitors of integrin function for clinical testing.
The binding site between the integrins and the related ligands consists in a short aminoacid 
stretches on exposed loops, particularly the arginine-glycine-aspartic acid (RGD) sequence 
(Figure 4.1). 
Figure 4.1. Binding of fibronectin (integrin ligand)  by integrin (transmembrane receptor). 
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The RGD sequence was identified in 1984 by Pierschbacher and Rouslahti as a minimal 
essential cell adhesion peptide sequence in fibronectin. [5] Since its discovery a great 
number of RGD containing drugs has been developed for different applications in cancer 
therapy. [3] The numerous advantages of RGD towards the use of entire proteins were 
suddenly recognised. The use of proteins, in fact, bears some disadvantages in the view of 
medical applications, e.g. the required purification, immune response, proteolytic 
degradation. [6-18] By using  small peptides as cell recognition motifs most of the 
problems listed above can be overcome. [19-26]  
In recent years, RGD-targeted drugs and imaging agents have been developed by covalent 
conjugation of the peptide to drug or to a carrier device that has been equipped with drug 
molecules or  in gene delivery by viral and non-viral vectors. Among this broad class of 
RGD-targeted drugs, the polymeric vectors showed the most promising features in cancer 
therapy because of their versatility and ease of synthesis.  The most used functional groups 
to provide a stable linkage between RGD and the polymer are amino, hydroxy and carboxy 
group. [27-31] The main obstacle to the coupling reactions is that there are further reactive 
functional groups in the RGD peptide. This problem can be overcome by using protecting 
groups or activating agents. 
In a more recent approach named chemoselective ligation, selected pairs of functional 
groups are used to form stable bonds without the need of an activating agent and without 
interfering with other functional groups. [32–34] As example, thiol (cysteine) bearing RGD 
peptides can be linked in a Michael addition reaction to acrylic esters or acryl amides with 
good yields. [7] 
In our group, poly(amidoamines)s (PAAs) containing RGD mimicking moieties were 
previously synthesised. [35] These polymers were obtained by polymerisation of agmatine, 
the de-carboxylation product of arginine, with N,N’-bisacryloyl-acetic acid (BAC) and by 
copolymerisation of agmatine and methylpiperazine (MP) with BAC. In biological tests 
these PAAs showed no cytoxicity and low or no haemolytic activity. Thus, we supposed 
that RGD containing PAAs could enhance the efficiency of RGD peptide in biological 
applications, without affecting its biochemical properties. 
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4.3Rationaleofthestudy
In a general sense, active peptides or peptido-mimetic substances constitute at present one 
of the frontier sectors of medicinal chemistry. Synthetic methods leading to polymers in 
which the peptide motif, DZ-linked by short connecting segments, is the major constituent 
could expand the range of applications in this sector. In this project, a novel synthetic 
procedure to obtain linear polymers, structurally related to PAAs, with short peptides 
inserted in the main chain is investigated. 
Poly(amidoamine)s (PAAs) are synthetic polymers characterised by the presence of tert-
amine and amide groups regularly arranged along the polymer chain (see Section 2). Linear 
PAAs are obtained by Michael-type polyaddition of primary monoamines or secondary bis-
amines to bis-acrylamides. [36,40] Primary bis-amines yield cross-linked polymers. [37,39] 
PAA-like polymers can be also prepared from bis-acrylamides and bis-thiols. [41] In early 
studies we observed that PAAs cannot be prepared using Ƚ-aminoacids as monomers, with 
the exception of glycine, because their primary amino group does not undergo a double 
addition step to bis-acrylamides. [36,37] Moreover, peptides initiating with substituted D-
aminoacid residues do not polymerise with bis-acrylamides. Glycine-initiated peptides give 
comb-like polymers with bisacrylamides with peptide residues as side substituents.        
[36-39, 42]  
L-Cystine is a natural bis-D-aminoacid derived from the oxidative coupling of two cysteine 
molecules. Its terminal primary amino groups are both substituted in the D position by the 
short chain interconnecting the two L-cysteine moieties. In our recent study, we have 
reported that L-cystine gives linear PAAs with typical bis-acrylamides, acting as a 
difunctional monomer in spite of having four mobile hydrogens. A kinetic study confirmed 
that each amine group of L-cystine undergoes a single addition step. [43] Moreover we 
have recently found that L-cysteine can be used as difunctional monomer with 
bisacrylamides to yield linear PAAs. [52] 
Summing up the above data, we concluded that any peptide carrying either two amino 
groups belonging to D-substituted aminoacid residues, or one of such groups plus a cysteine 
residue, or two cysteine residues will act as a difunctional monomer in stepwise Michael-
type polyadditions to bis-acrylamides giving linear polymers in which the peptide motifs 
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constitute the larger portion of the polymer chain (Figure 4.2). In the latter case, it is 
possible to obtain linear polymers also in the presence of amine groups in the peptide by 
carrying out the polymerisation at slightly acidic pH (see section 4.4). It follows that any 
natural or synthetic peptide can be converted into an DZ-difunctional monomer by adding 
one or two suitably selected aminoacid residues.
In this section, a novel method for preparing linear high polymers of peptides is presented. 
The feasibility of this synthetic method was demonstrated by obtaining linear polymers 
using  different molecules of high biological interest. The biological properties of the 
polymer synthesised are also discussed. 

Figure 4.2: general synthesis of PAAs containing peptides in the main chain. 
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4.4Resultsanddiscussion
To investigate the proposed synthetic method, the following peptide sequences were 
considered: reduced and oxidised glutathione, RGD, and ISLHA. In particular, 3 different 
series of polymers structurally related to PAAs were obtained by Michael polyaddition 
between N,N’-bisacryloylpiperazine (BP) or N,N’-bisacrylammidoacetic acid (BAC) with 
the following cysteine containing peptides, respectively: (i) reduced and oxidised 
glutathione, (ii) RGDC, CRGDC, (iii) ISLHAC and CISLHAC peptides (Figure 4.3). 
Moreover, the synthesis of polymers containing peptides by polyoxidation of  the thiol 
groups in DZposition of the peptide was investigated. Kinetic studies of these reactions 
and preliminary biological characterisation were also performed. 
Reduced L-glutathione (હ-L-glutamyl-L-cysteinyl-glycine) (GSH) is a natural peptide 
initiating by હ-carboxy-substituted aminoacid residue and containing a L-cysteine residue. 
Oxidised (dimerised) glutathione (GSSG) is a natural peptide carrying two હ-carboxy-
substituted aminoacid residues at the opposite termini. RGDC/CRGDC and 
ISLHAC/CISLHAC are derivatives of the well known biologically active RGD (L-arginyl-
glycyl-L-aspartic acid) and ISLHA (L-isoleucyl-L-seryl-L-leucyl-L-histidyl-L-alanine)
peptides, [44, 45] converted into difunctional monomers by introducing one and two L-
cysteine units, respectively. 
Figure 4.3: general synthesis of PAAs containing peptides in the main chain. 
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4.4.1PeptideSynthesis
The non commercially available peptides (RCGD, CRGDC, ISLHAC, CISLHAC) were 
synthesised by solid phase synthesis method (SPS) with a ABI 433 Peptide Synthesiser and 
Fmoc  based chemistry (see Chapter 6). As example, the synthesis of RGDC is reported 
(Scheme 4.1). The final step of the reaction is the cleavage of the peptide from the resin by 
stirring 4 h in TFA, with small amounts of water, thioanisol and ethane-1,2-dithiol as 
scavengers. The use of concentrate TFA permits the cleavage of all the acid-labile 
protecting groups of the aminoacid residues in the same step. Considering the conditions 
used for polimerisation reactions (see later), the peptides thus obtained can be used as 
difunctional monomer with the exception of ISLHAC peptide, since we found that the 
imidazole ring of the hystidine could react with the double bond of the bisacrylamide at pH 
9.5. (see Section 4.4.4). 
Scheme 4.1. Synthesis of RGDC by solid phase synthesis (SPS) method.  

After cleavage of protecting groups, the peptides were purified firstly by double 
precipitation with methanol/diethylic ether, to remove the thiols, secondly by HPLC 
(eluent: H2O/CH3CN), to remove the fractions of peptide with wrong sequence. The 
peptides were thus obtained with 70% - 80% of yield. All the peptides were characterised 
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by ESI Mass spectroscopy, NMR spectroscopy, Elmann’s assay and iodimetric titration 
(thiol groups concentration). 
4.4.2GlutathionecontainingPAAs
Reduced glutathione was used as monomer in polimerisation reaction, under standard PAA 
synthesis conditions, with N,N’-bisacryloylpiperazine (BP) and N,N’-bisacrylammidoacetic 
acid (BAC) obtaining polymers named BP-GSH and BAC-GSH, respectively. Moreover, 
each polymer was obtained in two different regioisomeric forms: in the first one, the GSH 
is randomly oriented along the macromolecular chain (“random” BP-GSH or BAC-GSH), 
in the second one, the GSH is orderly oriented along the main chain of the polymer 
(“ordered” BP-GSH or BAC-GSH) with a “head-to-head” sequence (Figure 4.4).  
Figure 4.4. Structures of “random” and “ordered” BP-GSH.  BP is N,N’-bisacryloylpiperazine and 
GSH is reduced glutathione. 
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This was achieved by carrying out the reactions with two different procedures (Scheme 
4.2): (1)The random polymer was obtained with a one step reaction, performed for 6 days 
at pH 9.5 with equimolar amount of GSH and bisacrylamide. At this value of pH, both thiol 
and amino group can react with the double bond of the bisacrylamide, giving a linear 
polymer in which the GSH residues are randomly oriented along the polymeric chain. 
(2)The ordered polymer is obtained in a two steps reaction: the first step is carried out for 
24 hours at pH 6.5 in presence of 1 equivalent of GSH and half equivalent of 
bisacrylamide. At this value of pH the amino group of GSH (pKa ̱ 9.6) is completely in its 
protonated form, then is not able to react with the double bond. On the contrary, the thiol 
group can react quickly with the double bond at pH 6.5. Therefore, a trimer ABA (where A 
is a GSH residue and B is a bisacrylamide residue), carrying two amino groups in the 
DZposition, is obtained. In the second step, carried out for 6 days, the pH value is 
increased to 9.5 and another half equivalent of bisacrylamide is added to the reaction 
mixture. In these conditions, the ABA trimer behaves like a secondary diamine, yielding a 
linear polymer in which the GSH residues are orderly oriented along the polymer main 
chain. As example, the 1HNMR spectrum of BP-RGDC is showed in Figure 4.5. Further 
studies will be performed to investigate possible differences between the behaviour of the 
“ordered and “random” polymers obtained, as for example in solubility and in degradation 
rate in physiological environment. 
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Scheme 4.2. One step and two steps synthesis method of  GSH containing PAAs.
Figure 4.5 HNMR spectra of random BP-GSH in D2O. 
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Oxidised glutathione (GSSG) was also used as monomer in polymerisation reactions with 
BP and BAC (Scheme 4.3), with the same conditions used for GSH containing PAAs 
(“random” BP-GSH). In this case, due to the structure of GSSG, carrying two amino groups 
with identical reactivity toward the double bond of the bisacrylamide, only the polymer 
with a random orientation of the GSSG residues along the polymeric chain was obtainable. 
Scheme 4.3. Synthesis of  GSSG containing PAAs.
By performing the reactions for 6 days, linear polymers with a number average molecular 
weight (ܯ௡തതതതሻ up to 18600 (see Table 4.1) were produced. In order to increase the final 
average molecular weight of the polymers, we extended the reaction time for more than 6 
days. However, after 8 days of reaction, the formation of partially crosslinked polymer was 
noticed in the reaction mixture. The insoluble product was filtered off, and the soluble 
fraction showed very high polydispersity (PD) values by GPC analysis. This is due to the 
fact that the secondary amino groups generated from the addition of the primary amino 
groups (of GSH or GSSG) to the double bond of the bisacrylamide can react again with the 
double bond. It follows that GSH and GSSG can behave as tri- and tetrafunctional 
monomers in polymerization reaction (Scheme 4.4).  
Scheme 4.4. Formation of crosslinked BP-GSSG polymer. BP is N,N’-bisacryloylpiperazine and 
GSSG is oxidised glutathione. 
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Anyway, the reaction rate of the addition of the secondary amino group is order of 
magnitude lower than that of primary amino group (see Section 4.4.5). Thus, below a 
reaction time of 6 days, we can consider that the obtained polymers are prevailingly linear. 
Therefore, all the polymerisation reactions were carried out for 6 days obtaining polymers 
with good yields (70% – 80%) and a ܯ௡തതതത ranging from 7800 to 18600 (Table 4.1). All the 
synthesised polymers were characterised by Gel Permeation Chromatography (GPC) and 
1HNMR spectroscopy. 
Polymer ࡹ࢔തതതത ࡹ࢝തതതതത PD yield 
BP-GSH random 12900 50700 3.9 87 % 
BP-GSH ordered 7800 18600 2.4 79 % 
BAC-GSH 10400 35000 3.4 75 % 
BAC-GSH 8300 23100 2.9 71 % 
BP-GSSG 18600 33100 1.8 80 % 
BAC-GSSG 10900 20200 1.8 85 % 
Table 4.1. GPC data of glutathione containing PAAs. Average molecular weights were measured 
by online Right (90°) and Low (7°) Angle Light Scattering detectors. 
4.4.3RGDcontainingPAAs
The RGD peptide was converted into difunctional monomers suitable for the Michael 
polyaddition with bisacrylamides, by adding either one cysteine moiety at the C-terminal, 
thus obtaining the RGDC peptide or two cysteine moieties at both C- and N-terminal, thus 
obtaining the CRGDC peptide. The polymerisation reactions were carried out in conditions 
similar to those used for glutathione containing PAAs (Scheme 4.5). RGDC containing 
polymers were obtained in both “random” and “ordered” form (see Section 4.4.2), applying 
the same method used for GSH containing PAAs (Section4.4.2). However, low molecular 
weight polymers were obtained. This is likely due to the strong intermolecular interactions 
generated in the reaction solution using K2CO3 as base to adjust the pH. 
In fact, we have found that using triethylamine (TEA), instead of K2CO3, to adjust the pH, 
the viscosity of the starting reaction solution was decreased, and the average molecular 
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weight  of the polymer increased 4-5 times (see Table 4.2). Moreover, since the oxidation 
by atmospheric oxygen of  the thiol groups of RGDC and CRGDC occurs at a relatively 
high rate, degassed water was used as reaction solvent and the reaction mixture was 
maintained under inert atmosphere. 
Scheme 4.5. Synthesis of  RGD containing PAAs. 
In the case of RGDC containing PAAs, the polymerisation reaction was carried out at pH 
9.5. At this pH, both thiol and amino groups can take part in the polyaddition reaction with 
the bisacrylamide. Indeed, about the 50 % of the amino group of RGDC (pKa ̱ 9.5) is in 
its unprotonated form, thus able to react with the double bond. Previous studies have shown 
that the side guanidine residue of arginine (pKa ̱ 12.5) under the pH conditions adopted 
does not participate in the addition reaction. Similar conditions were adopted for CRGDC 
containing PAAs, except the pH value, which was around 7, since at this value only the 
thiol groups are able to react, whereas the aminic nitrogen of the cysteine residue is 
completely in its protonated form. 
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Compared to glutathione, the modified RGD monomers displayed a lower reactivity 
towards the double bond of the bisacrylamide, resulting usually in longer reaction times, 
lower conversion and lower average molecular weights. The lower reactivity can be 
ascribed to the probable zwitterionic form of the modified RGD, which could alter the 
conformation of the molecule in solution. Moreover, these reactions were performed with a 
higher dilution (0.4 g of bisacrylamide per ml of water) of bisacrylamides compared to 
normal conditions for PAAs (1.6 g of bisacrylamide per ml of water) in order to limit the 
viscosity of the starting reaction mixture, that was higher than the one usually observed for 
GSH polymerisation reactions. In this case, the high viscosity is due intermolecular 
hydrogen bonds between the peptide molecules in water. Thus,  to minimize these 
interactions we performed the polymerisation of RGDC and CRGDC also with BAC. In 
fact, the carboxy group of BAC can limit peptide-peptide interactions. However, although 
the viscosity of the starting reaction mixture was visibly reduced, BAC exhibited lower 
reactivity compared to BP towards the peptides resulting in a longer reaction time and 
yielding polymers with lower molecular weight. All these polymers were characterised by 
GPC and 1HNMR. The 1HNMR spectra of BP-RGDC is showed in Figure 4.6. 
Figure 4.6 HNMR spectra of BP-RGDC in D2O.
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In order to vary the amount of RGD in the polymer, we performed the reaction between 
BAC and equimolar amounts of CRGDC and 2-methylpiperazine (MP), obtaining a 
copolymer ISA23-CRGDC (Scheme 4.6). The obtained polymers showed the presence of 
terminal double bonds. This is mainly due to the rapid oxidation of the thiol groups of the 
peptides that diminish the real concentration of thiol groups available for the addition 
reaction. It follows that, during the polymerisation reaction, the real concentration of thiol 
groups is slightly lower than that of double bonds, resulting in the presence of terminal 
double bonds in the final polymer. In these polymers terminal double bonds have to be 
eliminated since can lead to undesirable crosslinking of the polymer chains. Thus, at the 
end of the reaction, a 10 % of MP was added to terminate residual double bonds.   
This copolymer was obtained with high yield (75 %) and, thanks to the ISA23 repeating 
unit, showed a higher solubility in water compared to the others homopolymers containing 
RGD. By the 1HNMR spectra it was possible to calculate a CRGDC amount of 36 wt% in 
the polymer.  
Scheme 4.6. Synthesis of  ISA23-CRGDC copolymer. 
All the polymers shown so far in this study contain amide groups in the main chain, 
therefore they can undergo hydrolytic degradation (e.g. in biologic environment). In order 
to obtain an RGD containing PAA able to release the RGD peptide by reductive 
degradation, we have synthesised an ISA 23 containing RGDC as side substituent (Scheme 
4.7). The RGDC monomer was used in a substitution reaction involving the thiol group of 
the cysteine residue and the pendent disulfide linkages of the polymer ISA23-SS-Py (ܯ௡തതതത,
9500), that was synthesised as previously described. [47] The obtained polymer carries 
RGDC as side substituent and with a free amino group, suitable for further 
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functionalisations. Moreover, the disulfide linkage can be cleaved by a reductive agent, 
releasing the peptide. 
Scheme 4.7. Synthesis of  ISA23-SS-RGDC. 
A different synthetic strategy was used to obtain a polymer in which the CRGDC peptide is 
the unique constituent. Exploiting the high reactivity of thiol groups toward the oxidation to 
give disulfide linkages, we performed a polymerisation reaction by oxidating the thiol 
groups of CRGDC peptide in a concentrated solution (0.5 M). Unexpectedly, no 
polymerisation was observed by simply stirring the reaction mixture, containing CRGDC ( 
at pH 7), under air atmosphere. Instead, by using I2/KI as oxidating agent, polymerisation 
occurred with by far shorter reaction time (30 min) compared with the traditional method 
used for PAAs (Scheme 4.8). 
Scheme 4.8. Synthesis of  p(CRGDC). 
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The acetate buffer was used to quench the hydroiodic acid  formed as by product of the 
reaction. The p(CRGDC) displayed, as expected, a slightly lower solubility in water 
compared with the CRGDC peptide. Despite the high reaction rate observed, the molecular 
weight was in the range 3000 – 5000. The low average molecular weight can be addressed 
to the low monomer concentration (0.5 M) and to a probable cyclisation of the oligomers. 
The average molecular weights of the RGD containing PAAs are summarised in Table 4.2. 
Polymer ࡹ࢔തതതത ࡹ࢝തതതതത PD yield peptide  wt% 
BP-RGDC random 7200 22300 3.1 56 % 69 % 
BP-RGDC ordered 3200 6100 1.9 45 % 69 % 
BAC-RGDC random 2400 3400 1.6 52 % 69 % 
BAC-RGDC ordered 2800 4000 1.4 35 % 69 % 
BP-CRGDC 16700 39200 2.3 65 % 74% 
BAC-CRGDC 3000 7500 2.5 58 % 74% 
ISA23-CRGDC 5500 8000 2.3 75 % 36 % 
ISA23-SS-RGDC 12600 21000 1.7 91 % 60 % 
p(CRGDC) 3200 5000 1.6 86 % 100 % 
Table 4.2. GPC data of RGD containing PAAs. Average molecular weights were measured by 
GPC with online Right (90°) and Low (7°) Angle Light Scattering detectors. The yields are 
referred to the weight amount of the polymers ultrafiltered with a 1000 cutoff membrane, 
compared to the starting monomers. 
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4.4.4ISLHAcontainingPAAs
To obtain an DZ-difunctional monomer, the ISLHA peptide was modified by adding one 
cysteine moiety (ISLHAC) or two (CISLHAC) at the C-terminal or both C- and N-terminal 
of the peptide, respectively. By using the same procedure adopted for cysteine modified 
RGD, ISLHAC and CISLHAC were used as monomer in polymerisation reaction with BP 
(Scheme 4.9).
Scheme 4.9. Synthesis of  BP-ISLHAC and  BP-CISLHAC. 
The polymerisation of ISLHAC with BP, performed at pH 9.5, resulted in an insoluble 
product. This resulted from the cross-linking reaction of hystidine rings with bisacrylamide 
double bonds. By contrast, the polymerisation reaction involving CISLHAC peptide and 
BP, carried out at pH 6.5, produced a linear polymer. Therfore, the imidazole ring of 
hystidine is not able to react with the double bond at pH 6.5. To prove this, the reactivity of 
imidazole, chosen as a model compound for hystidine, with BP was investigated in D2O at 
9.5 and 6.5 by means of 1HNMR, which allowed monitoring the decrease in concentration 
of BP double bonds. As comparison, other two reactivity tests were carried out using 2-
mercaptoethanol, as model compound for the thiol group of the cysteine residue (Figure 
4.7). These results confirm that imidazole can react with BP at pH 9.5. Therefore the 
imidazole ring of the histidine could react with the double bond of BP at pH 9.5 and, 
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consequently, we can suppose that the ISLHAC monomer behaves as trifunctional 
monomer reacting with bisacrylamides at pH 9.5. 
Figure 4.7. Reactivity test between imidazole and BP at pH 6.5 and 9.5, and 2-mercaptoethanol with BP at 
pH 6 and 9.5. The integral value related to the double bond of BP is compared with the reference integral ( 
CH3 of tert-butanol). 
Instead, a linear polymer was obtained by performing the polymerisation at pH 6.5 with BP 
and CISLHAC. The polymer was obtained with low molecular weight ( Mn, 3000; Mw, 
4400; PD 1.47) and low yield (35 %). This is probably due to the low solubility of the 
peptide, caused by the presence of cysteine, leucine and isoleucine moieties, and to high 
viscosity of the reaction mixture, caused by intermolecular hydrogen bonds of hystidine 
and serine moieties. Anyway, thanks to the BP moiety, the polymer resulted more soluble 
in water than the related monomer. 
Based on the results presented above, we can conclude that the possibility to insert a 
peptide motif  in PAAs by using it as DZdifunctional monomer  is strongly dependent on 
the number and the type of aminoacids constituting the peptide. However, since it is well 
known that additional aminoacids flanked to the peptide do not affect its biological 
properties, it is possible to modify the peptide to adjust its solubility and to allow the 
reactivity in the polymerisation reaction at different pH. 
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4.4.5Kineticstudies
Extensive  kinetic tests were performed to study the behaviour of the peptide sequences 
used as DZ-difunctional monomer in polyadditions reactions with bisacrylamides. In 
particular, L- cysteine, reduced glutathione (GSH) and oxidised glutathione (GSSG) were 
used as model compound in Michael addition with dimethylacrylamide (DMA) ((a), (b) and 
(c) in Scheme 4.10, respectively).
Scheme 4.10. Studied reactions for kinetic tests.  
DMA was utilised instead of the traditional bisacrylamides used in PAA synthesis (e.g. BP, 
BAC) to avoid the increase in viscosity with the reaction progress. The kinetic tests were 
carried out at pH 9.5, 25°C and with a DMA concentration of 1.6 g per ml of water (the 
usual conditions for PAA synthesis). In these tests, 3/1 ratio between DMA and cysteine 
and GSH and 4/1 between DMA and GSSG were used. This ratios were chosen considering 
DMA as a monofunctional reagent, cysteine and GSH as trifunctionals, and GSSG as 
tetrafunctional (see Section 4.4.2). The decrease in double bond concentration during 
reaction was monitored by UV-visible spectrometry. 
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To understand the behaviour of these monomers in Michael addition we referred to our 
previous works on hydrogen transfer addition and polyaddition reactions involving 
acrylamides, bis-acrylamides, and/or bis-acrylic esters [47-50]. These kind of reactions 
exhibits pseudo-second-order kinetics, with the kinetic constants that include the 
concentration of the catalytic protonic species, when performed in the presence of hydroxyl 
solvents. Based on these premise, the decrease in DMA concentration ([DMA]) were 
plotted in conversion / time and [DMA]-1 / time graphs (see later). 
Kinetic “A”: DMA + cysteine 
For this test, a 3/1 DMA/cysteine ratio was used. In this case, we expected to observe two 
different conversion rates, since it is known from previous work that the thiol group can 
react faster than the amino group at pH 9.5. Effectively, it was found that by plotting the 
conversion rate of  DMA in 1/[DMA] versus time graph, the obtained curve was not linear, 
but diverged at about 50 % conversion (Figures 4.8 and 4.9). This result indicates the 
presence of two different reaction steps with different rates. In the first one the thiol group 
react with the double bond of DMA, until one equivalent of DMA is reacted. After that, the 
addition of the amino group to the double bond becomes prevailingly, consuming another 
equivalent of DMA. The best fitting conversion curve was calculated by numerically 
integrating the following differential equation: 
ௗሾ஽ெ஺ሿ
ௗ௧
ൌ െ݇ଵሾܦܯܣሿሾܵܪሿ െ݇ଶሾܦܯܣሿሾܰܪʹሿ      Equation 4.1
With    k1 = 1.1 x10-3 and k2 = 4 x10-5
where [DMA], [SH] and [NH2] represent the concentration of double bonds (of DMA), 
thiol groups and primary amino groups (of cysteine), respectively. The kinetic constants k1
and k2 of the two reaction steps were obtained by determining the slopes of the very initial 
and the very final segments of the 1/[BP] versus t curves (Figure 4.9), with the assumption 
that in either regions the reaction of one amino group of MP prevails over the other. 
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At the end of the reaction (40  days),  only two equivalents of DMA were consumed, 
indicating that cysteine behaves as difunctional monomer (Scheme 4.11) in Michael 
addition reaction to the double bond.  This behaviour is consistent with the one found for 
reaction between L-cystine (the L-cysteine dimer) and BP in a previous work. [47]  
Scheme 4.11. Addition steps in kinetic “A”. 
Figure 4.8.  Kinetic test “A”. After about 40 days (60000 min) only two equivalent of DMA were 
reacted. 
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Figure 4.9. Kinetic test “A”. Calculated conversion curves using the equation 4.1 (enlarged view). 
Kinetic “B”: DMA + GSH 
This kinetic test was performed with a 3/1 DMA/GSH ratio. GSH has one thiol and one 
primary amino group like L-cysteine. However, it was unexpectedly noticed that after 
approximately 10 days of reaction, more than 2 equivalents were reacted (Figure 4.10). 
This is due to multiple addition of the amino group to the double bonds of DMA. These 
results indicate that GSH could behave as trifunctional monomer in Michael addition with 
the double bond of DMA. In fact, by plotting the kinetic data in 1/[DMA] versus time
graph, three different reaction steps were observed (Figure 4.11). Therefore, the conversion 
curve was calculated by numerically integrating the following equation: 
ௗሾ஽ெ஺ሿ
ௗ௧
ൌ െ݇ଵሾܦܯܣሿሾܵܪሿ െ݇ଶሾܦܯܣሿሾܰܪʹሿ െ݇ଷሾܦܯܣሿሾܰܪʹԢሿ Equation 4.2 
where ௗሾேுଶ
ᇲሿ
ௗ௧
ൌ ݇ଶሾܦܯܣሿሾܰܪʹሿ,    k1 = 2.6 x10
-3
, k2 = 4 x10-4  and k3 = 6 x10-6
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where [DMA], [SH], [NH2] and [NH2’] represent the concentration of double bonds, thiol 
groups, primary amino groups and secondary amino groups (generated from the addition of 
the primary amino groups to DMA), respectively. The kinetic constants k1, k2 and k3 of the 
two reaction steps were obtained with the same method and the same assumptions of 
kinetic “A” (see above). In particular, k1, k2  and k3 are referred to addition to the double 
bonds by thiol groups, primary and secondary amino groups, respectively (Scheme 4.12). 
Scheme 4.12. Addition steps in kinetic “B”. 
Figure 4.10. Kinetic test “B”. After about 5 days (7000 min) more than two equivalent of DMA 
were reacted. 
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Figure 4.11. Kinetic test “B”. Calculated conversion curves using the equation 4.2. In the inset: 
enlarged view. 
Kinetic “C”: DMA + GSSG 
In this case, a 4/1  DMA/GSSG ratio was used. GSSG has only two identical primary 
amino groups and no thiol groups. As in the case of GSH a multiple addition step was 
observed for the amino groups and more than 2 equivalents of DMA were consumed after 
10 days of reaction.. However, only two different reaction steps were identified (Figure 
4.12 and 4.13), since in this case the addition of the thiol group is not present. Thus, the 
following differential equation was used to calculate the conversion curve by numerical 
integration:
ௗሾ஽ெ஺ሿ
ௗ௧
ൌ െ݇ଵሾܦܯܣሿሾܰܪʹሿ െ݇ଶሾܦܯܣሿሾܰܪʹԢሿ    Equation 4.3 
where ௗሾேுଶ
ᇲሿ
ௗ௧
ൌ ݇ଶሾܦܯܣሿሾܰܪʹሿ,    k1 = 1 x10
-4
 and k2 = 2 x10
-6
where [DMA], [NH2] and [NH2’] represent the concentration of double bonds, primary 
amino groups and secondary amino groups (generated from the addition of the primary 
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amino groups to DMA), respectively. The kinetic constants k1 and k2 indicate the addition 
to the double bonds of primary and secondary amino groups, respectively (Scheme 4.13). 
Scheme 4.13. Addition steps in kinetic “C”.

Figure 4.12. Kinetic test “C”.  After about 8 days (12000 min) more than two equivalent of DMA 
were reacted. 
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Figure 4.13. Kinetic test “C”.  Calculated conversion curves using the equation 4.3. 
Kinetic test Tested molecules k1 k2 k3
A DMA + cysteine 1.1 x10
-3
4 x10
-5
-
B DMA + GSH 2.6 x10
-3
 4 x10
-4
 6 x10
-6
C DMA + GSSG 1 x10
-4
 2 x10
-6
-
Table 4.3. Calculated kinetic constants for kinetic tests (a), (b) and (c). 
The values of the k1, k2, and k3 kinetic constants obtained for tests “A”, “B” and “C” are 
summarised in Table 4.3. It was previously demonstrated that the thiol group reacts with 
the double bond of a bisacrylamide faster than the amine group. [49] Thus, in cases “A”
and “B”, the higher kinetic constant (k1) can be addressed to the thiol group and, 
consequently, the lower (k2) refers to the amine group. Moreover, in the case “B” the 
lowest constant (k3) refers to the addition of the secondary amine group to the double bond 
(see above). In the case “C”, k1 and k2 indicate the addition of the primary and the 
secondary amino group, respectively. 
0,2
0,3
0,3
0,4
0,4
0,5
0,5
0,6
0,6
0,7
0 10000 20000 30000 40000 50000 60000
[D
M
A
]Ͳ1
(M
Ͳ1
)
Time(min)
Chapter  4 
105
No kinetic evidence of multiple addition steps to the primary amino group of L-cysteine 
molecule was found, confirming the previous studies on reaction between L-cystine and 
BP. [47] In contrast, multiple addition steps to the double bond were observed for amino 
groups of GSH and GSSG. Thus, in these molecules, the secondary amino group generated 
from the addition of the primary amino group to the double bond of the DMA can react 
again with another double bond. This is probably due by a catalytic effect of glutathione. 
This results are consistent with the experimental evidence  of partial crosslinking in 
polymerisation reaction of GSH and GSSG with BP (see Section 4.4.2). However, the 
reaction rate of the second addition of the amine group is some order of magnitude lower 
than that of primary addition,  and the effect (crosslinking) is evident only after at least 5 
days of reaction. Therefore, by adjusting the reaction time, is still possible to obtain linear 
polymers using these molecules as difunctional monomers. 
Finally, based on the structural resemblance of glutathione with RGD, and on the 
comparable results obtained in polymerisation reactions (see Section 4.4.2, 4.4.3), we can 
suppose that the behaviour of glutathione in this kind of polyaddition reaction is analogous 
to RGD peptide. 
4.4.6Biologicalproperties
Preliminary biological characterisations were carried out on BP-RGDC and BP-CRGDC by 
the group of prof. R. Cavalli (University of Turin). It was shown that both polymers have 
no haemolytic activity  at concentrations lower than 1.73 mg/ml (BP-RGDC) and 2.32 
mg/ml (BP-CRGDC). At the same concentration there was no evidence of cytotoxicity. 
The zeta potential measurement for both the polymers are shown in Figure 4.13. The values 
are negative (-5mV /-34 mV) in the pH range 5.0 – 7.4.  
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Figure 4.14. Zeta potential of BP-RGDC and BP-CRGDC. 
The negative values were expected since the carboxy group of the aspartic acid residue of 
RGD is deprotonated at physiologic pH. Moreover, negatively charged polymers usually 
show stealth properties when injected in vivo. Further in vitro tests are in progress to 
investigate the ability of these polymers in promoting  cellular adhesion, compared with the 
parent peptide. 
4.5Conclusions
A general synthetic methods to introduce a short peptide motif as main constituents of a 
polymer backbone was established. The new polymers were obtained by polyaddition of 
NH2- or SH –terminated peptides to bis-acrylamides and were therefore named 
“poly(peptamidoamine)s” (PPAAs) since they are based on peptides and are structurally 
related to PAAs.
BP and BAC were used as comonomers in polymerisation reaction with reduced and 
oxidised glutathione, cysteine modified RGD and cysteine modified ISLHA peptides, 
respectively, yielding polymers with a relatively high molecular weight.  
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Our experimental results suggest that this method could be extended, by adding the suitable 
aminoacid residues, to the preparation of polymeric peptides irrespective of the aminoacid 
sequence and the molecular weight of the parent peptide. In the resultant polymers, as in 
proteins, the peptide moieties constitute an integral part of the polymer chain in which they 
are inserted in DZ fashion. The polymerisation reaction takes place under remarkably 
friendly conditions, preserving the basic character of the amine group involved. Polymers 
obtained with BP as comonomers do not alter the acid-base properties of the parent 
peptides, as previously demonstrated. [46] By contrast, the presence of BAC can increase 
the anionic character and confer stealth-like properties to the polymer. [52] In addition, the 
RGD containing polymers showed no cytotoxicity and no haemolytic activity. The possible 
applications of PPAAs in biology, medicine and physics cannot be fully estimated at 
present, but are probably not negligible. Part of the work presented in this chapter has been 
published in an Italian Patent. [51] 
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Chapter5:Hyperbranchedpoly(amidoamine)sforgenedelivery
5.1Abstract
In this work gene delivery properties of new hyperbranched PAAs containing disulfide 
linkages in the main chain were investigated in comparison with the relevant linear 
polymers.  Eight different bioreducible poly(amidoamine)s (PAAs) were prepared by 
hydrogen-transfer polyaddition of N,N’-bisacryloylcystamine (CBA) with ethylenediamine 
(EDA) or N,N’-dimethylethylenediamine (DMEDA) and of N,N’-bisacryloylpiperazine 
(BP) with cystamine (CYST) or N,N’-dimethylcystamine (DMC). Each polymer was 
terminated with 4-aminobutanol (ABOL) and 2-ethanolamine (ETA). Remarkable results 
were obtained in DNA complexation tests, including particle size and zeta-potential 
measurement. DNA transfection experiments with COS-7 cells showed that polyplexes 
from hyperbranched CBA containing PAA give transfection higher or comparable with the 
relevant linear polymers and the branched pEI (reference polymer), and XTT assays 
displayed  low or no toxicity. Further tests are in progress to investigate the influence of 
terminal groups on the transfection capabilities of these polymers.  
5.2Introduction
Almost all human diseases have a genetic component, from untreatable monogenic 
disorders to cancer and heart disease. In recent years, gene therapy led to very promising 
results in many biomedical applications. The main objective in gene therapy is successful 
in vivo transfer of the genetic materials to the targeted tissues. Unfortunately, a suitable 
vector to deliver genes into cells which is both effective and safe is not yet available.[1] 
Vectors for gene delivery can be divided in two classes, viral and non viral. Viral vectors 
are obtained by modification of viruses to allow the delivery of foreign DNA. They possess 
a high transfection efficiency but, in the other hand, they have some drawbacks like 
immunologic reaction and low gene carrying capacity, resistance to repeated infection and 
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difficulty in production and quality control. Non viral vectors include naked DNA, 
oligonucleotide, lipoplexes and polymer DNA complexes (polyplexes). They showed 
interesting features in gene delivery. In fact, although they possess generally a lower 
efficiency in transfection compared to viral vectors, they have lower host immunogenicity, 
higher gene carrying capacity and can be obtained with simple large scale synthesis. In 
particular, synthetic polymers are very promising for applications in gene delivery since 
they allow a high level of design flexibility for biomaterial construction. Although the 
mechanism involved in gene delivery is not fully elucidated, it is known there are several  
extra- and intracellular barriers that a polymeric vector has to overcome in the delivery 
pathway. The cationic polymer-mediated gene delivery is illustrated Figure 5.1. 
DNA
Cationic
polymer
polyplexes
Cell
Lysosome
Endosome
Nucleus
Endocytosis
Figure 5.1. Schematic illustration of cationic polymer-mediated gene delivery.  
Hyperbranched poly(amidoamine)s for gene delivery 
112
Nano-sized polyplexes are formed by a self-assembling process between negatively 
charged DNA and cationic macromolecules due to electrostatic interaction. These 
polyplexes display a cationic surface charge and facilitate DNA cellular uptake by 
endocytosis. Within the endosome, the pH gradually decrease from 7.4 to about 4.5 
(lysosome). To avoid degradation by lysosomal enzymes, the polyplexes must escape from 
the endosome by some transmembrane mechanism or endosomolytic process like the 
“proton sponge effect”. [2] Once in the cytoplasm, the DNA must unpack from the particle 
and be carried into the nucleus, although these mechanisms are not fully understood. When 
DNA is introduced within the nucleus, gene expression and thus production of proteins 
occur.
It was found that good transfection efficiency is generally correlated with several features 
of polyplexes. In particular, polyplexes with size smaller than 200 nm and high stability in 
the extracellular environment display good transfection efficiency compared with bigger (or 
less stable) polyplexes. [3] Moreover, polyplexes’ efficient endosomal escape is achieved 
by using polymers with high buffer capacity [4] in the range of endosomal pH change (pH 
7.4 to 5.1) by “proton sponge effect”. Finally, therapeutic applications of these polymers 
can be seriously hampered by cytotoxicity.  
Two of the most widely investigated vectors for gene delivery are the cationic polymers 
polyethylenimine (PEI) and poly(L-lysine) (PLL) (Figure 5.1). PEI is a gene carrier with 
high transfection efficiency and high cytotoxicity. [5] Many factors affect the 
efficiency/cytotoxicity profile of PEI polyplexes such as molecular weight, degree of 
branching, ionic strength of the solution, zeta potential and particle size. [6,7] It was 
demonstrated that it is possible to minimize the toxicity of PEI by introducing acid-labile
imine linkers in the polymer. [8] The acid-labile PEI may be rapidly degraded into low 
molecular weight PEI in acidic endosomes. PEG-grafting of PEI also led to a decrease of 
the toxicity in vitro. [8,9] 
By contrast, PLL have a biodegradable nature since it is a linear polypeptide with the amino 
acid lysine as the repeat unit. However, when entered into the circulatory system, PLL 
polyplexes were rapidly bound to plasma proteins and cleared from the circulation. [10] 
This may cause lower transfection efficiency. Dendritic poly(L-lysine) of the 6th generation 
(KG6) showed high transfection efficiency, without significant toxicity or cell specificity. 
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As in the case of PEG-grafted PEI, the creation of amphiphilic PLL, by linking both PEG 
and palmitoyl groups to the polymer, reduced toxicity without compromising the gene 
delivery efficiency. [11] 
More recently, poly(amidoamine)s (PAAs) (Figure 5.1) begun to be studied as vector for 
gene delivery, showing promising results. As example, several amphoteric PAAs, carrying 
a carboxylic acid as side group in the bisacrylamide segment, synthesised by our group 
showed a DNA transfection ability comparable with PEI [12] and endosomolytic ability. 
[13] This can be explained by the capacity of these polymers to undergo conformational 
changes in the endosomal pH range. We also developed bioreducible PAAs containing 
disulfide linkages in the main chain, able to degrade in a reductive environment. [23] 
Moreover, Engbersen et al. developed a series of bioreducible PAAs containing disulfide 
linkages in the main chain with  DNA transfection ability higher than PEI. [14] These 
polymers were more efficient in DNA transfection than the related polymers lacking 
disulfide linkages. This can be ascribed to the biodegradability of the polymer in the 
intracellular environment. It was found also that, despite the cationic nature, these PAAs 
have low or no cytotoxicity.  Thus, poly(amidoamine)s can be regarded as promising 
vectors for the development of  high efficient and nontoxic polymeric gene carriers. 
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Figure 5.1. Structures of polyethylenimine (PEI), poly(L-lysine) (PLL) and poly(amidoamine)s 
(PAAs).
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5.3Rationaleofthestudy
Poly(amidoamine)s (PAAs) are polymers that can be easily synthesised by the Michael–
type polyaddition between bisacrylamides and primary mono-amines or secondary bis-
amines (See Section 2). PAAs displayed in different studies very promising features in 
gene delivery. [14, 15] Recently developed bioreducible PAAs containing disulfide 
linkages in the main chain showed better transfection than the related counterparts lacking 
disulfide linkages. This effect can be addressed to the biodegradability of the polymer in 
the intracellular environment. In previous works, it has been shown that partially degraded 
poly(amidoamine)s dendrimers (“activated PAMAM”) were able to transfect DNA more 
efficiently than non degraded dendrimers. [16] This is likely due to the higher structural 
flexibility in solution of partially degraded dendrimers. In a recent work,  it was found that 
hyperbranched poly(esteramine)s can transfect DNA with improved efficiency if compared 
with polyethylenimine (PEI) and poly(2-(dimethylamino)ethyl methacrylate) 
(pDMAEMA). Moreover, these hyperbranched poly(esteramine)s showed low or no 
toxicity in vitro. [17] 
Therefore, we supposed that an hyperbranched PAAs containing disulfide linkages in the 
main chain can have different advantages in DNA transfection compared with traditional 
linear PAAs. Firstly, in hyperbranched polymers the ratio between the number of terminal 
functions and the total number of monomeric units is higher than in linear polymers. Thus, 
by adding a suitable terminal group it is possible to improve the solubility in water of the 
polymer, and adjust the interaction between the polymer and the DNA. Secondly, the high 
density of secondary and tertiary amines can increase the buffering capacity over a wide pH 
range, promoting endosomal escape of polymer/DNA complexes by proton sponge effect. 
It was found also that the terminal groups of linear polymer can affect the transfection 
efficiency. [18] Thus, Hyperbranched PAAs could also be used as platform to investigate 
the effect of terminal groups. 
Based on these premises, we supposed that the hyperbranching can affect the transfection 
efficiency of PAAs. To investigate this hypothesis, we synthesized a new series of 
biodegradable PAAs (Figure 5.2) and tested their biological properties as well as the DNA 
transfection efficiency of polymer-DNA polyplexes. I performed this study at the Polymer 
Chemistry and Biomaterials (PBM) group (University of Twente, The Netherlands), in 
collaboration with the group of professor J.F.J. Engbersen. 
Hyperbranched poly(amidoamine)s for gene delivery 
116
5.4ResultsandDiscussion
5.4.1PAAsSynthesisandcharacterisation
In this study, 8 different biodegradable PAAs were synthesised and characterised (Figure 
5.2). In particular, 4 hyperbranched PAAs were obtained by Michael polyaddition between 
N,N’-bisacryloylpiperazine (BP) and cystamine (CYST) or N,N’-bisacryloylcystamine 
(CBA) and ethylenediamine (EDA). Each polymer was terminated with two different 
primary amines, 4-aminobutanol (ABOL) and 2-aminoethanol (ETA). In order to 
investigate the effect of hyperbranching, 4 linear PAAs, but structurally related to the above 
hyperbranched PAAs, were synthesised by polyaddition of  N,N’-dimethylethylenediamine 
(DMEDA) to CBA and of N,N’-dimethylcystamine (DMC) to BP. Also in this case each 
polymer was terminated with ABOL and ETA. All the synthesised polymers were 
characterised by Gel Permeation Chromatography (GPC) and 1HNMR spectroscopy. 

Figure 5.2.  General synthetic schemes and monomers utilised to obtain linear and hyperbranched PAAs.
Abbreviations: HB, hyperbranched; L, linear; CBA, N,N’-bisacryloylcystamine;  BP, N,N’-bisacryloylpiperazine; 
CYST, cystamine; DMC, N,N’-dimethylcystamine; EDA, ethylenediamine; DMEDA, N,N’-dimethyl-
ethylenediamine; ETA, ethanolamine; ABOL, aminobuthanol; -t, terminated.
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Linear PAAs were synthesised with reaction conditions similar to those of traditional PAAs 
(see Chapter 6). In the case of L-p(CBA-DMEDA) the polymerisation reaction was carried 
out in a 4/1 methanol/water mixture at 40 °C, since CBA monomer is not soluble in water.  
As secondary diamines, DMEDA and DMC were chosen because of their structural 
similarity with the amines used for the hyperbranched polymers syntheses (EDA and 
cystamine). In order to obtain hyperbranched PAAs, the difunctional amines used in the 
synthesis of linear PAAs were substituted with primary diamines (EDA and cystamine), 
that behave as tetrafunctional monomers under the reaction conditions adopted. The 
structures of the related polymers are shown in Figure 5.3. 
Figure 5.3.  Structures of linear and hyperbranched PAAs..
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Since the mechanism of polymerization of tetrafunctional monomers is more complicated 
than that of difunctional monomers, some consideration about this aspect are needed.
If the reactive functions of a tetrafunctional monomer have equal reactivity, nonlinear 
polymers and infinite networks as manifested by gelation are formed with predictable gel 
points [19,20]. In our case, however, the reactivity of tetrafunctional groups is unequal and 
many possible reaction routes exist. In particular, the addition rate  of the primary amino 
group to the double bond is higher than that of the secondary amino group generated from 
the first addition. The lower reaction rate related to the third and the fourth additions is 
presumably biased by a combination of steric hindrance and decrease in nucleophylicity 
due to substituents carrying electron-withdrawing carbonyl groups in Ⱦ position. Therefore, 
the polymerisation reaction can be divided in three phases; in the phase one the linear chain 
growth is prevailing, in the second phase the branching occurs, leading to crosslinking in 
the third phase. Moreover, second and third phases occur only with high conversion 
degrees.
In our recent work [21], a new approach was studied to determine the reactivity of different 
functions of a multifunctional monomers in order to obtain hyperbranched PAAs. In 
particular, stoichiometrically imbalanced reactant mixtures with excess of double bonds 
were used to adjust the degree of branching of the polymers. To determine the critical 
stoichiometric ratio “rc” , under which the system is unable to gel and yields hyperbranched 
but still soluble polymers, the following equation was used [20]: 
rc  
1
1 U f  2                         Equation 5.1 
Where:
rc = critical stoichiometric ratio (number of functions in defect / number of functions in 
excess)
U = the fraction of functions belonging to the monomer with functionality >2 with 
respect to the total amount of the functions of the same type initially present in the 
system. 
f = number of functions of the monomer with functionality >2  
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Operatively, a series of reactions with progressively larger excess of  double bonds were 
carried out for 6 days, and the reaction with the minimum double bonds excess inhibiting 
gelation of the polymer led to the rc value for that couple of monomers. The rc values found 
for the reactions involving the couples BAP/cystamine and CBA/EDA were 0.3083 and 
0.3312, respectively.  
All the synthesised PAAs showed good solubility in water and in buffer solutions. In the 
case of hyperbranched polymers, it was noticed the presence of insoluble particles at the 
end of the reaction. This particles were filtered off by ultrafiltration with a 100.000 cutoff 
membrane. The average molecular weight was measured by GPC with an online Refractive 
Index (RI) detector, PEG standards calibration, and a 8.5/1.5 sodium acetate 
buffer/methanol mixture as mobile phase.  The average molecular weight of the obtained 
PAAs ranged from 7800 to 30800.  It must be noted that the average molecular weights 
calculated for hyperbranched polymers could be underestimated, since they usually show a 
lower hydrodynamic volume compared with the linear counterparts.
1HNMR spectra confirmed the expected structures of linear and hyperbranched polymers. 
Moreover, there was no evidence of residual double bonds, that usually result in 
cytotoxicity of the polymer. To determine the degree of branching (DB) following equation 
was used [15]: 
ܦܤ ൌ ஽ା்
஽ା்ା௅
    Equation 5.2 
Where:
D = number of branching units  
T = number of terminal units   
L = number of linear units. 
A semiquantitative determination of the amount of terminal, linear and branched units was 
performed by 1HNMR. For all the hyperbranched polymers it was calculated a DB value of 
about 0.50. As example the 1HNMR spectrum of HB-p(CBA-EDA) (ABOL-t) is showed in 
Figure 5.4. 
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Figure 5.4. 1HNMR spectrum of HB-p(CBA-EDA) (ABOL-t) 
It has been shown that high buffer capacity can promote endosomal escape of 
polymer/DNA polyplexes by “proton spong effect”. Therefore, the buffer capacity of the 
polymers, defined as the percentage of amine groups becoming protonated in the pH range 
from pH 7.4 to 5.1, is a relevant parameter in the overall transfection process. The buffer 
capacity of the synthesised PAAs, together with PEI as a reference, is showed in Figure 5.5. 
The buffer capacity of the tested PAAs was generally higher compared to that of the 
reference polymer (commercial branched 25k polyethyleneimine (PEI)) and was slightly 
higher in the case of ETA terminated polymers compared with the ABOL terminated. 
Moreover, the BP seems to increase the buffer capacity compared to CBA, and there is no 
evidence of any influence of the branching.
The degradability of the polymers in a reductive environment was also verified by 1HNMR
specroscopy. In particular, the polymer solutions in D2O (0.1 M of disulfide linkages) were 
incubated with  2.4 equivalents of mercaptoethanol respect to the disulfide linkages 
concentration in the solution. After one hour, both hyperbranched and linear PAAs were 
completely degraded. Thus, it can be deduced that the hyperbranching does not affect the 
reductive degradation rate of PAAs. 
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Figure 5.5. Buffer capacity of the synthesised PAAs. Black bars, BP-containing PAAs; grey bars, 
CBA containing PAAs.
The GPC data and the buffer capacity values related to the obtained PAAs are summarised 
in Table 5.1. 
polymer ࡹ࢖ ࡹ࢔ ࡹ࢝ PD
Buffer
capacity (%) 
H
yp
er
br
an
ch
ed HB-p(BAP-CYST) (ABOL-t) 9400 10800 16300 1.51 37.96 
HB-p(BAP-CYST) (ETA-t) 12900 16900 22700 1.34 30.96 
HB-p(CBA-EDA) (ABOL-t) 6100 7800 14100 1.80 17.78 
HB-p(CBA-EDA) (ETA-t) 8900 11300 16400 1.45 19.39 
Li
ne
ar
L-p(BAP-DMC) (ABOL-t) 9300 9600 14800 1.54 23.12 
L-p(BAP-DMC) (ETA-t) 30700 30800 43300 1.41 32.44 
L-p(CBA-DMEDA) (ABOL-t) 12900 12500 18200 1.46 24.41 
L-p(CBA-DMEDA) (ETA-t) 10700 10500 14800 1.41 32.00 
Table 5.1. GPC data and buffer capacity of the synthesised PAAs. 
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5.4.2DNAcomplexationandrelease
A fundamental feature that a polymer needs in gene delivery is the ability of complex DNA 
into nanosized polyplexes. Generally, to be efficiently endocytosed by cells, polyplexes 
must have an overall positive surface charge and a average size smaller than about 200 nm. 
Therefore, zeta-potential and particle size of polymer-DNA polyplexes were measured with 
polymer/DNA ratios of 48/1, 12/1, 3/1 and 1/1. The zeta-potential and particle size values 
of the PAAs, measured by Dynamic Light Scattering (DLS), are showed in Figures 5.6 and 
5.7. 
Figure 5.6. Particle size (above) and zeta-potential (below) values of the BP containing PAAs. 
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As expected from a previous work, [22] CBA containing PAAs were more effective in 
transfection than BP containing PAAs. This could be attributed to the lower flexibility of 
the macromolecular chain, due to the piperazine ring. HB-(BP-CYST) (ETA-t) showed a 
transfection efficiency comparable with PEI only at polymer/DNA ratios of 48/1 and 
12/1(only without FBS).
The best transfection efficiency was obtained with the polymer HB-p(CBA-EDA) (ABOL-
t) at a polymer/DNA ratio of 6/1, without FBS. Unexpectedly, the transfection efficiency of 
hyperbranched (HB-) polymers was generally enhanced in presence of FBS than without. 
This result is encouraging for in vivo testing of these polymers. 
In general, the effect of hyperbranching on transfection is not constant, although in most of 
the cases hyperbranched (HB-) polymers showed better transfection than the related linear 
(L-) polymers. Moreover, the effect of the terminal group (ABOL and ETA) was negligible 
and only in the case of HB-p(CBA-EDA) (ABOL-t) the transfection efficiency was clearly 
enhanced by ABOL if compared with ETA. 
The cytotoxicity is another fundamental parameters affecting the transfection process.
The polyplexes cytotoxicity for all the polymers, at the same polymer/DNA ratios used in 
transfection tests, was also measured by XTT assay (Figures 5.10 and 5.11). 
Figure 5.10. Cell viabilities related to BP containing polymers.
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Figure 5.11. Cell viabilities related to CBA containing polymers.
All the PAAs tested displayed low or no cytotoxicity. Moreover, it was unexpectedly found 
that hyperbranched (HB-) PAAs show generally less cytotoxicity than the related linear   
(L-) PAAs. The presence of FBS caused for most of the PAAs a slight decrease in toxicity. 
Remarkable toxicity was found only for HB-(CBA-EDA) at a polymer DNA ratio of 48/1, 
irrespective of the terminal group. A constant effect on cell viability of the terminal groups 
(ABOL and ETA) is not evident. Moreover, the difference in toxicity between PAAs 
ABOL or ETA terminated in the linear PAAs is not enhanced in the related hyperbranched 
PAAs.
Summarising the results discussed above, the studied PAAs showed low or no cytotoxicity 
at all the tested polymer/DNA ratios. In transfection tests, the best performing polymer was 
HB-p(CBA-EDA) (ABOL-t) at a polymer/DNA ratio of 6/1 with transfection efficiency 
higher or comparable with PEI. In general, the hyperbranched polymer showed a higher 
transfection efficiency than the linear counterparts, although the enhancement seems to be 
strongly dependent on the polymer structure and the polymer/DNA ratio.
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5.5Conclusions
Eight novel kind of hyperbranched and linear PAAs containing disulfide linkages in the 
main chain, and different terminal functions were synthesized and characterized. These 
PAAs are able to undergo reductive degradation in a reductive environment (i.e. inside 
cells). The polymers’ transfection efficiency was tested and compared. CBA containing 
polymers showed a DNA transfection efficiency comparable with PEI and performed 
mostly better than polymers containing BP. Better results were obtained with 
hyperbranched PAAs  in comparison with the linear PAAs and, in particular, the 
hyperbranched CBA containing PAA ABOL terminated (HB CBA-EDA (ABOL-t)) 
showed the highest transfection efficiency. Anyway, clear correlations  between the 
hyperbranching, and the transfection efficiency  are not readily apparent. Despite of their 
cationic nature, these hyperbranched PAAs displayed low or no toxicity.
At the moment further tests are in progress with these hyperbranched and linear polymers 
terminated with ethylenediamine (EDA). In the future, it could be interesting to investigate 
the effect in transfection of the hyperbranched polymers varying the amount of the disulfide 
linkages, or varying the terminal functions.  
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Chapter6:ExperimentalPart

Materials 
All solvents were of analytical grade purchased from ALDRICH, FLUKA or LAB-SCAN 
and used as received. Lithium chloride monohydrate, NaOH pellets, 37% hydrochloric acid 
(HCl), 1,2-diaminoethane (EDA), sodium bicarbonate, potassium  bicarbonate, 
triphenychloromethane, N,N’-ethylenediamine-diacetic acid (EDDA), 2-aminoethyl-
phosphonic acid (AP), N,N’-dimethylethylenediamine (DMEDA), N,N’-
bisacryloylcystamine (CBA), cystamine (CYST), 4-aminobutanol (ABOL), 2-ethanolamine 
(ETA) were purchased from FLUKA at the highest purity and used without further 
purifications. Fmoc-protected aminoacids (L-cysteine, L-aspartic acid, glycine, L-arginine, 
L-hystidine, L-leucine, L-isoleucine, L-alanine, L-serine), cysteine loaded Wang resin, N-
methylpirrolydone (NMP), HBTU, diisopropylethylamine (DIPEA), tri-fluoroacetic acid, 
ethylic ether, piperidine, dichloromethane, dimethylformamide, thioanisol, 1,2-
ethanedithiol, acetonitrile (HPLC grade) were purchased at peptide grade from Biosolve 
and used without further purifications. 
 2-methylpiperazine (MP) (from FLUKA) was re-crystallised from n-heptane and its purity 
determined titrimetrically just before use.
Methods 
Polymers average molecular weight: The molecular weight and polydispersity (ܯ௡തതതത/ܯ௪തതതത) of 
the synthesized poly(amido amine)s were determined by GPC with three different systems: 
x System 1: WATERS 515 HPLC Pump instrument, with Toso-Haas 486 columns, 
pullulan standards (Aldrich) calibration, using Tris buffer pH 8.00 r0.05 as mobile 
phase. Conditions: sample concentration 10mg/ml; flow rate 1ml/min.; Detectors: 
Waters 486 Tunable Absorbance Detector (UV), wavelength 230 nm and Waters 
2410 Refractive Index Detector (RI); room temperature (~24°C). Data collected with 
Cirrus GPC Software (MS Windows). 
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x System 2: Knauer Pump 1000 with a Knauer Autosampler 3800, with Toso-Haas 
486 columns, using Tris buffer pH 8.00 r 0.05 as mobile phase. Conditions: the 
same used in System 1; Detectors: Right (90°) Angle Light Scattering, Low (7°) 
Angle Light Scattering detector and Waters 2410 Refractive Index Detector (RI); 
room temperature (~24°C). Data collected with Omnisec software (MS Windows). 
x System 3: PL-GPC 120 system (Polymer Laboratories) and two thermostated (30ºC) 
PL aquagel-OH 30 columns (8 ȝm, 300×7.5 mm, Polymer Labs, with a low-molar-
mass separation range (200׽100,000) and PEG standards (Polymer Labs) 
calibration. 0.3 M sodium acetate aqueous solution (pH 4.5) was used as eluent at a 
flow rate of 0.5 mL/min. Data were collected using a Refractive Index detector (RI) 
with Cirrus GPC Software (MS Windows).  
NMR: 1HNMR and 13CNMR spectra were recorded on Bruker spectrometers operating at 
and 400 MHz (Bruker 400 Ultrashield), respectively. Polymer samples were prepared by 
dissolving about 10 mg of polymer  in salt-free form,  in 1 mL of D2O. 
Buffer capacity: the buffer capacity of the PAA polymers was determined by acid-base 
titration. An amount equal to 5 mmol of amine groups of the PAA polymer was dissolved 
in 10 mL of 150 mM NaCl aqueous solution. The pH of the polymer solution was set at 2.0 
and the solution was titrated with 0.1 M NaOH solution using an automatic titrator 
(Metrohm 702 SM Titrino). For comparison, branched PEI (Mw=25 kDa) dissolved in 150 
mM aqueous solution adjusted to pH 2.0, was also titrated using the same method. The 
buffering capacity defined as the percentage of amine groups becoming protonated from pH 
5.1 to 7.4, was calculated from equation 1: 
NMol
MVcityBufferCapa NaOH 1.0(%) u'    Equation 6.1 
Wherein ǻV NaOH, is the volume of NaOH solution (0.1 M) required to bring the pH 
value of the polymer solution from 5.1 to 7.4, and N mol (5 mmol), is the total moles of 
protonable amine groups in PAA polymer. 
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Particle size and zeta-potential measurements: the surface charge and the size of polyplexes 
were measured at 25 °C with a Zetasizer 4000 (Malvern Instruments Ltd., Malvern, UK). 
PAA/plasmid DNA polyplexes at a polymer/DNA mass ratio of 12/1 were prepared by 
adding a HEPES buffer solution (20 mM, pH 7.4, 5 wt% glucose) of poly(amidoamine)s 
(800 ȝL, 225 ȝg/mL) to a HEPES buffer solution of plasmid DNA (200 ȝL, 75 ȝg/mL), 
followed by vortexing for 5 s and incubating at room temperature for 30 min. 
In vitro transfection and cell viability assays: Transfection experiments were performed 
with COS-7 cells (SV-40 transformed African Green monkey kidney cells) by using the 
plasmid pCMV-LacZ. [1,2] Two parallel transfection series, one for the determination of 
reporter gene expression (ȕ-galactosidase) and the other for the evaluation of cell viability 
by XTT assay, were carried out in separate 96-well plates (ca. 1.0 × 104 cells per well). 
Different polymer/plasmid DNA weight ratios, ranging from 12/1 to 48/1 (w/w), were used 
to prepare the polyplexes. In brief, polyplexes were prepared by adding 200 ȝL of a HEPES 
buffer solution (20 mM, 130 mM NaCl, pH 7.4) of poly(amidoamine) with varying 
concentrations (from 37.5 to 150 ȝg/mL) to 50 ȝL of a HEPES buffer solution of plasmid 
DNA (50 ȝg/mL), followed by gentle shaking and incubating at room temperature for 30 
min. All transfection and toxicity assays were carried out in triplo. In a standard 
transfection experiment, the cells were incubated with the desired amount of polyplexes 
(100 ȝL dispersion with 1 ȝg plasmid DNA per well) for 1 h at 37 °C in a humidified 5% 
CO2-containing atmosphere. Next, the polyplexes were removed. 100-ȝL of fresh culture 
medium was added and the cells were cultured for 2 days. The transfection efficiency was 
determined by measuring the activity of ȕ-galactosidase using the ONPG assay. [1]             
A poly(ethyleneimine)(PEI)/DNA formulation prepared at a polymer/DNA ratio of 3/1 
(w/w) was used as a reference. [1] The number of viable cells was measured using an XTT 
assay [3]. The XTT value for untreated cells (i.e. cells not exposed to the transfection 
medium) is taken as 100% cell viability. 
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Reductive degradation studies of  PAAs:
The selected PAA (700 mg, 0.4 mmol of repeating unit) was dissolved in a D2O (4 ml). The 
homogeneous solution obtained was maintained at 25°C under nitrogen atmosphere while 
stirring, and then 2-mercaptoethanol (70 mg; 0.88 mmol) added. An aliquot of solution (1 
ml) was taken after 1 h and analysed by 1HNMR.
Determination of free –SH groups with Ellman’s reagent:
The unknown concentration of thiol groups in peptide samples were determined by 
comparison with an amino acid standard, L-cysteine. First, various concentrations of L-
cysteine (10-2 – 10-6 mol/L) were prepared in TRIS buffer (pH 8). A solution of Ellman’s 
reagent was freshly prepared in TRIS buffer (4.2 mg in 1 ml). 250 ρl of L-cysteine solution 
Were diluted with 2.5 ml of TRIS and 50 ρl of Ellman’s reagent solution were added. The 
sample is incubated at room temperature for 15 min. Subsequently, absorbance is read at 
412 nm using TRIS as blank. A concentrated solution of L-cysteine alone in TRIS buffer 
did not show any absorbance at 412 nm. 
Scheme 6.1. Ellman’s reagent addition reaction to thiols. 
Fractionation procedure with a solvent non solvent method: a solution of MeOH and H2O
9:1 was saturated with LiCl. The polymer batch was dissolved in this solution in the highest 
concentration affordable. A solution of acetone saturated with LiCl was added drop wise 
into the polymer batch until a precipitate is formed. The solid was recovered through 
centrifugation and the liquid was kept in a flask. The white solid was washed 3 times with a 
solution of the same composition of the solution where it precipitated and dried under 
vacuum. The liquid part kept in a flask was used to start again the procedure adding drop 
wise acetone and waiting for a precipitation. 
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Nanoparticles coating tests: diethyleneglycol (DEG) solution of nanoparticles in (0.2 g in 
40 ml of solvent) was added dropwise to an aqueous solution of the polymer (1.2 g in 200 
ml) under stirring. The resulting solution, was stirred for about 10 minutes and then was 
ultrafiltered with a 30000 cutoff dialysis tube to eliminate low molecular weight species, 
uncoated nanoparticles and polymer in excess. Ultrafiltration with Amicon (Millipore) 
system gave rapid precipitation of nanoparticles due to the magnetic field generated by the 
stirrer.
Synthesis of RGDC peptide: 
The peptides were synthesized by the solid-phase method [4] with trityl polymer-bound 
resin cysteine-functionalized at a substitution level of 0.9 mmol/g, 0.3 g of resin was used 
for each synthesis. All amino acids were protected with (9-fluorenylmethyl)carbamate  
(Fmoc). Aminoacids were loaded in this order: first, aspartic acid, second, glycine and 
third, arginine. Each synthetic cycle consisted of (i) a 20-min Fmoc deprotection of the 
aminoacid bound to the resin with piperidine, (ii) washing of the resin with N-
methylpyrrolidone (NMP), (iii) double coupling with each aminoacid activated with a 0.5 
M solution of  both O-benzotriazole-N,N,N’,N’-tetramethyluronium-hexafluoro phosphate 
(HBTU) and N-Hydroxybenzotriazole (HOBt) in DMF (3 eq. of the Fmoc-amino acid 
respect to 1 eq. of resin) for 1 h each in NMP. All couplings were monitored by 
conductimetric measuring of Fmoc concentration on waste solvent. Protected peptide-resin 
was first cleaned with CH2Cl2, then dried in vacuo up to a constant weight (0.3-0.4 g); 
afterwards the peptide cleavage from both the resin and all the protective groups was 
performed with  tri-fluoroacetic acid (TFA) (20 mL) and H2O, 2,2-ethandithiol and 
thioanisole (1 ml of every) for 2 hours. The unblocked resin was filtered, and the peptide 
was precipitated with diethyl ether and filtered off. Later the peptide was purified by 
gradient HPLC (solution A: H2O with 0.1 % v/v of TFA; solution B: CH3CN/Sol.A 1/1) 
and finally was obtained with yield of 85% w/w. Purity (Ellman's assay), 98.4 %. The 
product was stored at -18°C under inert atmosphere. 1H NMR  (D2O) į=2.85 (dd, HS-CH2-
CH); 4.76-4.78 (m, HS-CH2-CH(COOH)-NH); 2.91-2.97 (m, HN-CO-CH2-CH); 4.56 (t, 
CH2-CH(COOH)-NH); 4.06 (dd, HN-CO-CH2-NH); 3.95 (t, CO-CH(NH2)-CH2); 1.8-1.71 
(m, CH(NH2)-CH2-CH2); 1.91-1.93 (m, CH2-CH2-CH2-NH); 3.22 (t, CH2-CH2-NH-
C(NH2)=NH).
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13C  NMR (D2O): į=35 (HS-CH2-CH); 50 (HS-CH2-CH(COOH)-NH); 172 (HS-CH2-
CH(COOH)-NH); 172 (HN-CO-CH2-CH); 25 (HN-CO-CH2-CH); 55 (CH2-CH(COOH)-
NH); 174 (CH2-CH(COOH)-NH); 171 (HN-CO-CH2-NH); 52 (HN-CO-CH2-NH); 170 
(NH-CO-CH(NH2)-CH2); 42 (NH-CO-CH(NH2)-CH2); 23 (CH(NH2)-CH2-CH2); 28 (CH2-
CH2-CH2-NH); 40 (CH2-CH2-NH-C(NH2)=NH).   
MS (70 eV): m/z = 450 (M+) (calculated, 449.5). 
Synthesis of CRGDC peptide: 
The synthesis was carried out by using the same procedure of RGDC synthesis, but with 
this sequence of aminoacids: aspartic acid, glycine, arginine, and cysteine. Yield 82 % w/w. 
Purity (Ellman’s assay), 97.6 %. The 1H NMR spectra of CRGDC is qualitatively the same 
of RGDC, but in that of CRGDC all cysteine peaks (1H: 2.85, 4.76) have double intensity. 
The 13C spectra are also similar.
MS (70 eV): m/z = 552.3 (M+) (calculated, 552.3).  
Synthesis of CISLHAC peptide:
The synthesis was carried out by using the same procedure of RGDC synthesis, but with 
this sequence of aminoacids: alanine, hystidine, leucine, serine, isoleucine, and cysteine. 
Yield 71 % w/w. Purity (Ellman’s assay), 98.2 %. 1H NMR (D2O) į=0.84 (b, (CH3)2-CH,
Ile, Leu); 1.34 (d, CH3-CH, ala); 2.92 (m, CH-CH2-SH, cys); 3.75 (d, CH-CH2-OH, ser); 
4.30 (m, CH-CH2-CH, hys).
13C  NMR (D2O): į=39.0 ( CH-CH2-CH, hys); 16.3 ( (CH3)2-CH, Ile); 10.4 ( CH3-CH,
ala); 36.2 ( CH-CH2-SH, cys); 22.0 ( CH-CH2-OH, ser); 25.7 ( (CH3)2-CH, Leu);
MS (70 eV): m/z = 746 (M+) (calculated, 745.91). 
Synthesis of  ISLHAC peptide:
The synthesis is carried out by using the same procedure of RGDC synthesis, but with this 
sequence of aminoacids: alanine, hystidine, leucine, serine, and isoleucine. Yield 75 % 
w/w. Purity (Ellman’s assay), 96.5 % . The 1H NMR spectra of CISLHAC is qualitatively 
the same of ISLHAC, but in that of CISLHAC all cysteine peaks (1H: 2.85, 4.76) have 
double intensity. The 13C spectra are also similar.
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MS (70 eV): m/z = 642 (M+) (calculated, 642.77). 
Synthesis of the monomers:
2,2-Bisacrylamido acetic acid (BAC) and 1,4-bisacryloylpiperazine (BP) were synthesised 
as previously described,(BP, [5] BAC, [6]) and their purity determined titrimetrically 
(BAC) or by NMR spectroscopy (BP) just before use. N,N’-dimethylcystamine (DMC) was 
synthesised as described in literature [7]. N-triphenylmethyl-monosubstituted 1,2-
diaminoethane was synthesized as previously described [8] . 
Syntheses of PAAs:
ISA 23 and the related copolymers were synthesised as previously described: ISA 23 and 
ISA23-Tyr, [9] ISA23-Ⱦ-CD [10] and ISA23-NH2. [8] 
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BAC-EDDA: In a 10 ml round bottom flask, bidistilled water (1.6 ml) was added. Under 
stirring, LiOH*H2O (618mg; 14.75 mmol) and EDDA (865 mg; 4.91 mmol) were added in 
this order. After the reagents were completely dissolved, BAC (purity, 97.4 %; 1.0 g; 4.91 
mmol) was added to the solution. Then the reaction was gently stirred for 48 hours under 
inert atmosphere (N2) and in the dark. After this time the mixture was diluted to 20 ml with 
water, acidified to pH 4.5 with 37% HCl and ultrafiltered through 3000 cut-off membrane 
to eliminate the excess of low molecular weight species (unreacted monomers, LiCl). 
Finally the product was freeze-dried and stored at -20°C. ࡹ࢔തതതത: 20000; PD: 1.66 (by GPC 
System 1). Yield: 87 % w/w. 1HNMR (D2O): į (ppm) = 2.75 (H9, H10) (4H, m,); 5.53 (H4) 
(1H, s,); 3,50 -3,70 (H7, H8, H11)(12H, b). 

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Scheme 6.2. Structure of BAC-EDDA
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Figure 6.1. 1HNMR spectrum of BAC-EDDA in D2O at 25 °C. 
BAC-AP: In a 10 ml round bottom flask, 5 M aqueous NaOH solution (2.980 g) and then 
AP (621.1 mg; 4.96 mmol) were added under stirring. After the reagent was completely 
dissolved, BAC (purity, 97.4 %; 1.0 g; 4.91 mmol) was added to the solution. Then the 
reaction was gently stirred for 72 hours under inert atmosphere (N2) and in the dark. After 
this time the mixture was diluted to 20 ml with water, acidified to pH 4.5 with 37% HCl 
and ultrafiltered through 3000 cut-off membrane to eliminate the excess of low molecular 
weight species (unreacted monomers, NaCl). Finally the product was freeze-dried and 
stored at -20°C.ࡹ࢔തതതത: 22500; PD: 1.49 (by GPC System 1).
 1HNMR (D2O): į (ppm) =
2.05(H10) (2H, m,); 2.85 (H1, H8) (4H, b); 3.39 (H9)(2H, b); 3.49 (H2, H8) (4H, b); 5.70 
(H4) (1H, s) 

Scheme 6.3. Structure of BAC-AP
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Figure 6.2. 1HNMR spectrum of BAC-AP in D2O at 25 °C. 
BP-EDDA: In a 10 ml round bottom flask, bidistilled water (1.6 ml) was added. Under 
stirring, LiOH*H2O (425mg; 10.1 mmol) and EDDA (907.2 mg; 5.15 mmol) were added in 
this order. After the reagents were completely dissolved, BP (1.0 g; 5.15 mmol) was added 
to the solution. Then the reaction was gently stirred for 48 hours under inert atmosphere 
(N2) and in the dark. After this time the mixture was diluted to 20 ml with water, acidified 
to pH 4.5 with 37% HCl and ultrafiltered through 3000 cut-off membrane to eliminate the 
excess of low molecular weight species (unreacted monomers, LiCl). Finally the product 
was freeze-dried and stored at -20°C. ࡹ࢔തതതത: 25200; PD: 1.66 (by GPC System 1).
  1HNMR 
(D2O): į (ppm) = 2.93(H4) (4H, m,); 3.54 (H1) (8H, b); 3,58 -3,65 (H2, H3)(8H, b); 3.80 
(H5) (4H, b). 
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Scheme 6.4. Structure of BP-EDDA
Figure 6.3. 1HNMR spectrum of BP-EDDA in D2O at 25 °C. 
BP-AP: In a 10 ml round bottom flask, 5 M aqueous NaOH solution (2.060 g) and then AP 
(644.0 mg; 5.15 mmol) were added under stirring. After the reagent was completely 
dissolved, BP (1.0 g; 5.15 mmol) was added to the solution. Then the reaction was gently 
stirred for 72 hours under inert atmosphere (N2) and in the dark. After this time the mixture 
was diluted to 20 ml with water, acidified to pH 4.5 with 37% HCl and ultrafiltered through 
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3000 cut-off membrane to eliminate the excess of low molecular weight species (unreacted 
monomers, NaCl). Finally the product was freeze-dried and stored at -20°C.ࡹ࢔തതതത: 20600; 
PD: 1.25 (by GPC System 1). 1HNMR (D2O): į (ppm) = 1.99 (H5) (2H, m); 2.98 (H3) (4H, 
b); 3.36 (H4)(2H, b); 3.43 (H2) (4H, b); 3.54 – 3.59 (H1) (8H, s). 

Scheme 6.5. Structure of BP-AP 

Figure 6.4. 1HNMR spectrum of BP-AP in D2O at 25 °C. 
BAC-EDDA-Tyr: working as described in BAC-EDDA synthesis, the following reagents 
were added to the reaction flask in this order: H2O (1.6 ml), LiOH*H2O (211.4 mg; 5.04 
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mmol),  BAC (purity, 97.4 %; 1.0 g; 4.91 mmol), EDDA (778.5 mg; 4.419 mmol), 
tyramine (purity: 98 %; 67.4 mg; 0.511 mmol). The polymer thus obtained can be 
radiolabeled with 125I as previously described [11]. The polymer was purified as described 
in BAC-EDDA synthesis.ࡹ࢔തതതത: 15300; PD: 1.24 (by GPC System 1).
  1HNMR (D2O): The 
spectrum of BAC-EDDA-Tyr is qualitatively the same of BAC-EDDA, but in that of BAC-
EDDA-Tyr the peaks of tyramine (į (ppm) = 7.19 – 6.86) are also evident. Amount of  
tyramine: 7.5 % of the tyramine containing repeating units over total number of repeating 
units.
BAC-EDDA-NH2: working as described in BAC-EDDA synthesis, the following reagents 
were added to the reaction flask in this order: H2O/MeOH 2/1 (1.6 ml), TEA (purity 99 %; 
515 mg; 5.04 mmol), BAC (purity, 97.4 %; 1.0 g; 4.91 mmol), EDDA (778.5 mg; 4.419 
mmol), N-triphenylmethyl-1,2-diaminoethane (148.48 mg; 0.491 mmol). After 24 h 0.5 ml 
of water are added to the solution, stirring for 3 days. The protecting group of the primary 
amino group was removed by adding to the solution 2ml of water and adjusting to the pH 
of 2 with HCl 2M and stirring for 2 hours more. The polymer was purified as described in 
BAC-EDDA synthesis. ࡹ࢔തതതത: 3200; PD: 1.28 (by GPC System 1).
 1HNMR (D2O): The 
spectrum of BAC-EDDA-NH2 is qualitatively the same of BAC-EDDA, but in that of 
BAC-EDDA-NH2 the peaks of EDA (į (ppm) = 3.80 – 3.96 (-CH2-CH2-NH2)  (4H, b)) are 
also evident. Amount of  EDA: 7.0  % of the EDA containing repeating units over total 
number of repeating units. 
BAC-EDDA-ȕ-CD: working as described in BAC-EDDA synthesis, the following reagents 
were added to the reaction flask in this order: H2O 1.6 ml, NaHCO3 (412.5 mg; 4.91 
mmol), BAC (purity, 97.4 %; 1.0 g; 4.91 mmol), EDDA (778.49 mg; 4.419 mmol), mono-
6-deoxy-6-amino-ȕ-cyclodextrin (556.7 mg; 0.491 mmol). The polymer was purified as 
described in BAC-EDDA synthesis.ࡹ࢔തതതത: 21800; PD: 1.36 (by GPC System 1).
  1HNMR
(D2O): į (ppm) = 5.01 (anomeric hydrogen of ȕ -CD)  (7H, b); see BAC-EDDA spectrum. 
1HNMR (D2O): The spectrum of BAC-EDDA-ȕ-CD is qualitatively the same of BAC-
EDDA, but in that of BAC-EDDA-ȕ-CD the peaks of ȕ-CD (į (ppm) = 5.01 (anomeric 
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hydrogen of ȕ -CD)  (7H, b)) are also evident. Amount of ȕ -CD: 8 % of the ȕ -CD 
containing repeating units over total number of repeating units. 
BP-GSH (random): in a 10 ml round bottom flask, BP (306.5 mg, 1.579 mmol) was 
dissolved in water (0.54 ml). Reduced L-glutathione (GSH) (500.2 mg, 1.578 mmol) and 
potassium carbonate (220.3 mg, 1.578 mmol), in this order, were added under nitrogen and 
the resultant solution (pH # 9.5) was gently stirred 6 days at 20° under nitrogen. The 
mixture was then diluted to 100 ml with water, acidified to pH # 4.5 with hydrochloric 
acid, ultrafiltered through a membrane with nominal cut-off 5000 and freeze-dried. ࡹ࢔തതതത:
12900; PD: 3.9 (by GPC System 2). Yield 86.9 % w/w. 
1H NMR (D2O): į = 3.62 (CH2-CH(NH2)-COOH); 3.6 (NH-CH2-COOH); 4.5 (CH2-
CH(NHCO)-CONH); 2.75-3 (S-CH2-CH); 2.4 (CONH-CH2-CH2); 3.3 (NH-CH2-CH2);
2.95 (CH2-CH2-CON); 2.10 (CH2-CH2-CH); 3.75 (piperazine ring); 3.0 (NCO-CH2-CH2);
2.8 (CH2-CH2-S).
13C  NMR (D2O): į = 62.5 (CH2-CH2-COOH); 45 (NH-CH2-COOH); 53 (CH2-
CH(NHCO)-CONH); 33 (S-CH2-CH); 32 (CONH-CH2-CH2); 43 (NH-CH2-CH2); 29 
(CH2-CH2-CON); 25 (CH2-CH2-CH); 42 (piperazine ring); 28 (NCO-CH2-CH2); 34 (CH2-
CH2-S); 170-174 (quaternary carbons)  
Elemental analysis (C20H32.51 N5O8.7Cl0.125S)n (501.56)n: Calculated, C = 46.31, H = 6.32, O 
= 26.83, N = 13.50, S = 6.18, Cl = 0.85; Found C = 44.02, H  = 5.85, O = 26.34,  N =12.72, 
S  = 5.84; Cl = 0.82. 
Specific rotation [Į]20589 =  -17.5 deg·dm-1·g-1·cm3
BP-GSH (ordered): this reaction is carried out in two steps. In the first step, water (0.54 
ml), BP (153.3 mg; 0.7895 mmol), GSH (500.2 mg; 1.578 mmol) and potassium carbonate 
(110.1 mg; 0.7895 mmol), in this order, were added in a 10 ml reaction flask and the 
resultant solution (pH # 6.5) was stirred for 24 hours at 20° under nitrogen. Afterwards, BP 
(153.3 mg; 0.7895 mmol) and potassium carbonate (110.1 mg; 0.7895 mmol) were added 
and the resultant solution (pH # 9.5) was stirred for 6 days at 20° under nitrogen. 
Purification was done as BP-GSH (random). ࡹ࢔തതതത: 7800; PD: 2.4 (by GPC System 2). Yield
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79.4 % w/w. The 1H NMR and 13C NMR  spectra of the BP-GSH (ordered) is qualitatively 
the same of BP-GSH (random). 
BAC-GSH (random): this polymer was prepared as BP-GSH (random) starting from water 
(0.54 ml), BAC (purity 97.4 %; 321.26 mg; 1.579 mmol), GSH (500.2 mg, 1.578 mmol) 
and potassium carbonate (440.6 mg, 3.156 mmol). ). ࡹ࢔തതതത: 10400; PD: 3.4 (by GPC System 
2). Yield 75 % w/w. The 1H NMR and 13C NMR  spectra of the BAC-GSH (random) is 
qualitatively the same of BP-GSH (random) but in that of BAC-GSH (random) the peaks of 
BP are substituted by those of BAC (1H NMR (D2O): į =3.07 (4H, b); 3.27 (4H, b); 5.47 
(1H, s)). 
BAC-GSH (ordered): this polymer was obtained as BP-GSH (ordered) starting from water 
(0.54 ml), BAC (purity: 97.4; 160.63 mg; 0.7895 mmol), GSH (500.2 mg; 1.578 mmol) and 
potassium carbonate (110.1 mg; 0.7895 mmol) in the first step, and  BAC (purity: 97.4; 
160.63 mg; 0.7895 mmol) and potassium carbonate (110.1 mg; 0.7895 mmol) in the second 
step.ࡹ࢔തതതത: 8300 PD: 2.9 (by GPC System 2). Yield 71.8 % w/w. The 
1H NMR and 13C
NMR  spectra of the BAC-GSH (ordered) is qualitatively the same of BAC-GSH (random). 

BP-GSSG: this polymer was prepared as BP-GSH starting from BP (194.0 mg, 0.999 
mmol), water (0.75 ml), oxidized L-glutathione (645.2 mg, 1.000 mmol) and potassium 
carbonate (152.7 mg, 1.093 mmol). ࡹ࢔തതതത: 18600; PD: 1.8 (by GPC System 2). Yield 80.3 % 
w/w. 
1H NMR (D2O): į = 3.65 (CH2-CH(NH2)-COOH); 3.6 (NH-CH2-COOH); 4.75 (CH2-
CH(NHCO)-CONH); 2.8-3.2 (S-CH2-CH); 2.5 (CONH-CH2-CH2); 3.9 (piperazine ring); 
2.9 (NCO-CH2-CH2); 3.25 (NH-CH2-CH2).
13C  NMR (D2O): į = 62 (CH2-CH(NH2)-COOH); 53 (NH-CH2-COOH); 39 (CH2-
CH(NHCO)-CONH); 29 (S-CH2-CH); 43 (CONH-CH2-CH2); 29 (piperazine ring); 25 
(NCO-CH2-CH2); 44 (NH-CH2-CH2); 170-175 (quaternary carbons) 
Elemental analysis (C30H49.7 N8O15.8Cl0.3S2)n (806.89)n: Calculated, C = 42.33, H = 5.89, O 
= 29.70, N = 13.16, S = 7.53, Cl = 1.37; Found C = 39.95, H  = 5.63, O = 29.36,  N =12.57, 
S  = 7.4; Cl = 1.36. 
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Specific rotation [Į]20589 =  -70.3 deg·dm-1·g-1·cm3
BAC-GSSG: this polymer was prepared as BP-GSSG starting from BAC (purity 97.4 %; 
321.26 mg; 1.579 mmol), GSSG (970.45 mg; 1.579 mmol) and potassium carbonate 
(220.59 mg, 1.579 mmol). ࡹ࢔തതതത: 10900; PD: 1.8 (by GPC System 2). Yield 85 % w/w. The 
1H NMR and 13C NMR  spectra of the BAC-GSSG is qualitatively the same of BP-GSSG 
but in that of BAC-GSSG the peaks of BP are substituted by those of BAC (1H NMR 
(D2O): į =3.07 (4H, b); 3.27 (4H, b); 5.47 (1H, s). 
BP-RGDC: In a 10 ml round bottom flask RGDC (purity: 98.4 %; 91.26 mg; 0.20 mmol) 
was added under a moderate nitrogen flow, followed by 0.300 ml of degassed and 
bidistilled water. Afterwards, BP (38.8 mg; 0.2 mmol) was added under stirring to the flask. 
After the reagents were completely dissolved, triethylamine (TEA) (purity: 99%; 20.44 mg; 
0.2 mmol) was added to the solution (pK: 9.0-9.5). Then the reaction was gently stirred for 
8 days under inert atmosphere (N2) and in the dark. After this time the mixture was diluted 
to 20 ml with water, acidified to pH 4.5 with 37% HCl and ultrafiltered through 1000 cut-
off membrane to eliminate the excess of low molecular weight species (unreacted 
monomers, TEA). Finally the product was freeze-dried and stored at -20°C. ࡹ࢔തതതത: 7200; PD: 
3.1 (by GPC System 2). Yield: 56 % w/w. 
1H NMR  (D2O, all broad peaks): į = 1.62 (2H, CH(NH2)-CH2-CH2-NH, Arg); 1.93 
(CH(NH2)-CH2-CH2-NH, arg); 3.57-3.67 (8H, piperazine ring); 4.29 (S-CH2-CH(COOH)-
NH, CYS); 3.99 (CO-CH2-CH(COOH)-NH, asp).




Scheme 6.6. Structure of BP-RGDC.

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Figure 6.5. 1HNMR spectrum of BP-RGDC in D2O at 25 °C. 
BP-CRGDC: this polymer was prepared as BP-RGDC starting from CRGDC (purity: 97.6 
%; 113.24 mg; 0.2 mmol), bidistilled and degassed water (0.300 ml), BP (38.8 mg; 0.2 
mmol) and TEA (20.44mg; 0.2 mmol) to obtain a final solution pH of 6.5-7.0. The reaction 
was terminated after 6 days. ࡹ࢔തതതത: 16700; PD: 2.3 (by GPC System 2). Yield: 65 % w/w. 
1H NMR  (D2O, all broad peaks): į = 1.60 (2h, CH(NH2)-CH2-CH2-NH, Arg); 1.90 
(CH(NH2)-CH2-CH2-NH, arg); 3.57-3.67 (8H, piperazine ring); 4.29 (S-CH2-CH(COOH)-
NH, cys); 3.99 (CO-CH2-CH(COOH)-NH, asp).
13C NMR (D2O): į=35 (HS-CH2-CH, cys); 50 (HS-CH2-CH(COOH)-NH, cys); 173 (HS-
CH2-CH(COOH)-NH, cys); 172 (HN-CO-CH2-CH, gly); 27 (HN-CO-CH(CH2-COOH-
NH, asp); 60 (HN-CO-CH(CH2-COOH)-NH, asp); 173 (CH2-CH(COOH)-NH, cys); 170 
(HN-CO-CH2-NH, gly); 52 (HN-CO-CH2-NH, gly); 168 (NH-CO-CH(NH2)-CH2, cys); 42 
(NH-CO-CH(NH2)-CH2, cys); 23 (CH(NH2)-CH2-CH2, arg); 28 (CH2-CH2-CH2-NH, arg); 
40 (CH2-CH2-NH-C(NH2)=NH, arg); 32 (piperazine ring). 

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
Scheme 6.7. Structure of BP-CRGDC. 

Figure 6.6a. 1HNMR spectrum of BP-CRGDC in D2O at 25 °C. 
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Figure 6.6b. 13CNMR spectrum of BP-CRGDC in D2O at 25 °C. 
BAC-RGDC : this polymer was prepared as BP-RGDC starting from RGDC (purity: 98.4 
%; 91.26 mg; 0.20 mmol), BAC (purity: 97.4%; 40.69 mg; 0.20 mmol) and TEA (purity: 
99%; 20.44 mg; 0.2 mmol). ࡹ࢔തതതത: 2400; PD: 1.6 (by GPC System 2).
   Yield 52.5 % w/w. 
The 1H NMR and 13C NMR  spectra of the BAC-RGDC is qualitatively the same of BP-
RGDC but in that of BAC-RGDC the peaks of BP are substituted by those of BAC (1H
NMR (D2O): į =3.07 (4H, b); 3.27 (4H, b); 5.47 (1H, s). 
p(CRGDC): in a 10 ml round bottom flask, CRGDC (purity: 97.6 %; 46.0 mg; 0.08142 
mmol) was dissolved in water (0.300 ml) and TEA (purity: 99%; 10 mg; 0.0978 mmol) was 
added to the solution. Afterwards, a sodium acetate buffer solution (pH ؆ 6.0) (0.700 ml) 
containing I2 (10.5 mg/ml of buffer) and KI (25 mg/ml of buffer) was added to the reaction 
mixture under stirring. The polymer was then precipitated by adding ethanol, centrifuged, 
washed again with ethanol and then diethyl ether, and finally dried with N2 flow. ). ࡹ࢔തതതത:
3200; PD: 1.6 (by GPC System 2). Yield 86 % w/w. 
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ISA23-SS-RGDC: in a 10 ml round bottom flask, the polymer ISA23-SS-Py [12] 
(149.5mg; 0.4727 mmol of repeating units) and RGDC (purity: 98.4 %; 50.79 mg; 0.1112 
mmol)  were dissolved in Tris buffer (pH ؆ 8.0) and stirred overnight at room temperature. 
.ࡹ࢔തതതത: 12600; PD: 1.7 (by GPC System 2). Yield 91 % w/w. The 
1H NMR and 13C NMR  
spectra of the ISA23-SS-RGDC are qualitatively the same that ISA23, but in that of ISA23-
SS-RGDC characteristic peaks of RGDC are also evident (see above). 
BP-CISLHAC: : this polymer was prepared as BP-CRGDC starting from CISLHAC 
(purity: 98.2 %; 151.91 mg; 0.2 mmol), bidistilled and degassed water (0.400 ml), BP (38.8 
mg; 0.2 mmol) and TEA (20.44mg; 0.2 mmol) to obtain a final solution pH of 6.5Ǧ͹ǤͲ. The 
reaction was terminated after 8 days. ࡹ࢔തതതത: 3000; PD: 1.47 (by GPC System 2). Yield: 35 
% w/w. 
1H NMR  (D2O, all broad peaks): į = 0.84 (b, (CH3)2-CH, Ile); 1.27 (CH3-CH, ala); 4.33 
(m, CH-CH2-CH, hys); 3.55 (8H, piperazine ring). 


Scheme 6.8. Structure of BP-CISLHAC.

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Figure 6.7. 1HNMR spectrum of BP-CISLHAC in D2O at 25 °C. 

HB-p(BP-CYST): cystamine dihydrocloride (purity: 98 %; 309.0 mg; 1.345 mmol)  and BP
(1694.3 mg; 8.723 mmol)  were dissolved in water (5.0 ml) in a 10 ml round-bottom flask. 
The pH was then adjusted to 9.0-9.5 by adding CsCO3. The reactant solution was stirred at 
room temperature for 3 days under inert atmosphere and in the dark. The solution was then 
diluted with 20 ml of water, acidified at pH 4.5 with HCl 37 %, ultrafiltrated (1000 cut-off 
membrane) and freeze-dried. Afterwards, the polymer (510 mg; 1.47 mmol of repeating 
units) was dissolved in MeOH (5.20 ml) and then 40 mol% excess of ABOL (or ETA) was 
added to consume the terminal acrylamide groups and stirring was continued for 24 hours 
at room temperature. Finally, the solution was diluted with water (20 ml), acidified to pH 
4.5 with HCl 37 %, ultrafiltered (1000 cut-off membrane) and freeze-dried. ࡹ࢔തതതത: 10800; 
PD: 1.51 (by GPC System 3). Yield 40% w/w.  Insoluble aggregates were eliminated by 
ultrafiltration (100,000 cut-off membrane). 1H NMR (D2O, all broad peaks): į = 1.44 (H3) 
(2H, m); 1.58 (H2) (2H, m); 3.44 (H5, piperazine ring) (8H, b); 2.50 – 3.0 (H7b, H8, H9) 
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(6H, b); 3.0 – 3.60 (H6b, H8b, H9b, b) (6H, b); 2.93 (H1) (2H, t); 3.44 (H4) (2H, t); 3.15 
(H6) (4H, b); 2.75 (H7) (4H, b). 
Scheme 6.9. Structure of HB-p(BP-CYST). 
Figure 6.8. 1HNMR spectrum of HB p(BP-CYST) (ABOL-t) in D2O at 25 °C. 
L-p(BP-DMC): in a 10 ml round-bottom flask, bidistilled water (1.80 ml), N,N’-
dimethylcystamine dihydrocloride (DMC) (599.6 mg; 2.367 mmol) and N,N’-bisacryloyl
piperazine (BP) (460mg; 2.368 mmol)  were added in this order. The pH was then adjusted 
to 9.5-10 by adding TEA (479.3 mg; 4.760 mmol). The reactant solution was stirred at 
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room temperature for 3 days under inert atmosphere and in the dark. Afterwards, 10 mol% 
excess ABOL (or ETA) was added to consume any unreacted acrylamide groups and 
stirring was continued for 24 hours. The solution was then diluted with 20 ml of water, 
acidified at pH 4.5 with HCl 37%, ultrafiltrated (cutoff membrane 1000) and freeze-
dried.ࡹ࢔തതതത: 9600;  PD: 1.54 (by GPC System 3).  Yield 87% w/w.
1H NMR  (D2O, all broad 
peaks): į = 1.43 (H3) (2H, m); 1.66 (H2) (2H, m); 3.44 (piperazine ring) (8H); 3.49 (H4) 
(2H, b); 3.08 (H1) (2H, b); 3.31 (H6, H9) (8H, b); 2.87 (H7, H8) (8H, b). 
Scheme 6.10. Structure of L-p(BP-DMC). 
Figure 6.9. 1HNMR spectrum of L-p(BP-DMC) (ABOL-t) in D2O at 25 °C. 
Chapter  6 
153

HB-p(CBA-EDA): this polymer was prepared as HB-p(BAP-CYST) starting from a 
solution MeOH/bidistilled water 5.395/1, EDA (purity 99.5 %; 82 mg; 1.3576 mmol) and 
CBA (2143 mg; 8.2303 mmol). The reaction was carried out at 40 °C for 5 days. End-
capping of the terminal double bonds and purification were performed as HB-p(BAP-
CYST).ࡹ࢔തതതത: 7800; PD: 1.80 (by GPC System 3).  Yield 38% w/w. Insoluble aggregates 
were eliminated by ultrafiltration (cutoff 100,000). 1H NMR  (D2O, all broad peaks): į = 
3.35 (H7, H7b) (4H, b); 2.68 (H8, H8b) (4H, b); 3.13 (H6) (4H, t); 2.53 (H5) (4H, t); 2.7 – 
3.0 (H9b) (4H, m); 2.4 – 2.5 (H9) (4H, b); 2.91 (H1) (2H, t); 1.57 (H2) (2H, m); 1.43 (H3) 
(2H, m); 3.44 (H4) (2H, t).
Scheme 6.11. Structure of HB-p(CBA-EDA).
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Figure 6.10. 1HNMR spectrum of HB p(CBA-EDA) (ABOL-t) in D2O at 25 °C. 
L-p(CBA-DMEDA): this polymer was prepared as L-p(BAP-DMC) starting from 4.34 ml 
of a solution MeOH/bidistilled water 4.636/1, N,N’-dimethylethylenediamine (DMEDA) 
(purity: 99 %; 508.9 mg; 5.715 mmol) and N,N’-bisacryloylcystamine (CBA) (1488.2 mg; 
5.715). The reaction was carried out at 40 °C for 5 days. End-capping of the terminal 
double bonds and purification were performed as L-p(BAP-DMC). ࡹ࢔തതതത: 12500;  PD: 1.46 
(by GPC System 3). Yield 75% w/w.1H NMR  (D2O, all broad peaks): į = 2.60 (H10) (6H, 
b); 3.21 (H9) (4H, b); 2.68 (H8) (4H, t); 3.15 (H6) (4H, b); 2.56 (H5) (4H, b); 3.36 (H7) 
(8H, b). 
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Scheme 6.12. Structure of L-p(CBA-DMEDA). 
Figure 6.11. 1HNMR spectrum of L-p(CBA-DMEDA) (ABOL-t) in D2O at 25 °C. 
The 1HNMR spectra of ETA terminated polymers are qualitatively the same of ABOL 
terminated polymers, but in those of ETA terminated all ABOL peaks (1H: 1.60, 1.40 ppm) 
are not present, whereas peak at 3.50 (2H) and 2.80 (2H) ppm are observed. 
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All the 1H NMR spectra of the PAAs showed above display many broad or overlapped 
signals (between 2.5 and 4.5 ppm). This is due to the coupling of nuclear spins of several 
di-methylene groups. This is not unexpected. In NMR spectra of small molecules, these 
interactions are averaged to zero by rapid, isotropic tumbling. However, in polymeric 
solutions, the molecular motion is slow enough that this coupling can contribute 
significantly to the peaks definition.
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